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 Abstract 
 Umbilical cord matrix stem (UCMS) cells are derived from Wharton’s jelly and 
have been shown to express genes characteristic of primitive stem cells.  They can be 
isolated in large numbers in a short time and thus potentially represent an abundant 
source of cells for therapeutic use.  We investigated the migratory nature of human 
UCMS cells towards MDA 231 human breast carcinoma cells in an in vitro model of cell 
migration; UCMS cells cultured with or without MDA 231 cells for 24 hours.  Next, we 
evaluated the effect of chemokines, stromal derived factor 1 (SDF-1) and vascular 
endothelial growth factor (VEGF) on human UCMS cells by treating with increasing 
doses of SDF-1 and VEGF.  UCMS cells were found to migrate towards MDA 231 cells 
in a dose dependent manner.  Both SDF-1 and VEGF induced migration of UCMS cells 
in a dose dependent manner.  These results suggest that MDA 231 cells might be 
releasing chemokine factors, such as SDF-1 and VEGF, which promote UCMS cell 
migration towards the tumor cells in vitro.  Stem cells that migrate to tumors may allow 
targeted delivery of therapeutic agents that otherwise may have severe side effects.  To 
evaluate the selective engraftment and therapeutic efficiency of human UCMS cells that 
were engineered to express interferon beta (UCMS-IFN-β), MDA 231 cells (2 x 106) 
were intravenously injected into severe combined immune deficient (SCID) mice, 
followed by three weekly intravenous injections of fluorescently labeled UCMS-IFN-β 
cells (0.5 x 106).  To evaluate the synergistic effect of 5-Fluorouracil (5-FU) and IFN-β, 
MDA 231 cells were intravenously injected into SCID mice, followed by three weekly 
intravenous injections of fluorescently labeled UCMS-IFN-β cells and three weekly intra 
peritoneal injections of 5-FU.  In both of the above experiments, mice were euthanized 
 one week after the last UCMS cell transplant and lung weights were compared to the 
controls to determine the differences in tumor burden.  After transplantation of UCMS-
IFN-β cells into MDA 231 tumor-bearing mice, UCMS cells were found near or within 
metastatic lung tumors but not in other tissues, and in these animals, the lung weight 
was significantly less than MDA 231 tumor-bearing animals that received saline 
injections.  Histologically, there was significant reduction in the tumor area in MDA 231 
tumor bearing lungs after UCMS-IFN-β treatment.  When 5-FU was given along with 
UCMS-IFN-β cells, there was further reduction in tumor area.  These results indicate 
that UCMS cells can potentially be used for targeted delivery of cancer therapeutics.  
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intravenous injections of fluorescently labeled UCMS-IFN-β cells and three weekly intra 
peritoneal injections of 5-FU.  In both of the above experiments, mice were euthanized 
 one week after the last UCMS cell transplant and lung weights were compared to the 
controls to determine the differences in tumor burden.  After transplantation of UCMS-
IFN-β cells into MDA 231 tumor-bearing mice, UCMS cells were found near or within 
metastatic lung tumors but not in other tissues, and in these animals, the lung weight 
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CHAPTER 1 - BACKGROUND AND SIGNIFICANCE 
STEM CELLS  
Stem cells are defined as unspecialized (undifferentiated) cells that have the 
ability to self renew and differentiate into multiple cells or tissues (Caplan, 1991).  The 
most primitive stem cell is the fertilized oocyte.  The daughter cells of the first two 
divisions of the fertilized egg are totipotent cells, which are able to differentiate into all 
three germ layers (ectoderm, mesoderm and endoderm) including extra embryonic 
membranes.  There are two broad categories of stem cells: embryonic stem cells and 
adult stem cells.  Embryonic stem cells (ESC) are derived from the inner cell mass of 
the mouse/human blastocyst, 5 days after an egg is fertilized (Evans and Kaufman, 
1981).  ESCs are pluripotent cells; they can differentiate into any cell/ tissue type except 
extra embryonic membranes (Nagy et al., 1990).  ESCs express pluripotent stem cell 
markers, such as Oct-4, Sox-2, and Nanog and these transcription factors ensure the 
suppression of genes that lead to differentiation (Adewumi et al., 2007).  Though ESCs 
were shown to differentiate into several cell types and used for replacement therapies, 
the major drawback of these cells is that they form tumors when transplanted in large 
numbers (Thomson and Marshall, 1998;Arnhold et al., 2004).  There are moral/ethical 
concerns regarding human ESCs since they are derived from human embryos or 
human fetal tissues (Vats et al., 2002). 
Most adult tissues have multipotent stem cells that have the property to 
differentiate into more than one germ layer but not all types.  Adult stem cells, such as 
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hematopoietic stem cells and bone marrow-derived mesenchymal stem cells (MSC), 
also known as marrow stromal cells are harvested from adult bone marrow (Werts et al., 
1980).  Other sources of adult stem cells include MSCs derived from adipose tissue, 
umbilical cord blood, placenta, amniotic fluid, perivascular areas and from umbilical cord 
matrix (Campagnoli et al., 2001;Zuk et al., 2001;Mitchell et al., 2003a;Tsai et al., 
2004;Sarugaser et al., 2005b).  Another source of adult stem cells are neural stem cells 
derived from both developing and adult brain (Palmer et al., 1997).  Stem cells with their 
unique self renewal and migratory ability in response to chemotactic factors have a 
great potential to be used as gene delivery agents in various autoimmune and 
debilitating diseases. 
UMBILICAL CORD MATRIX STEM CELLS 
The umbilical cord, found in amniotes is a cord that connects fetus to the 
placenta.  The umbilical cord consists of two arteries (umbilical artery), a vein (umbilical 
vein), and surrounding connective tissue matrix, also called ‘Wharton’s jelly’.  The 
umbilical cord helps in transport of nutrients and oxygen rich blood between fetus and 
placenta.  The origin of umbilical cord is still unclear; the Wharton’s jelly contains 
mesenchymal like cells surrounded by extracellular matrix.  The extracellular matrix 
contains abundant collagen and glycosaminoglycans (70% of which is hyaluronidase).  
During the last decade, umbilical cord blood has been extensively used for therapeutic 
purposes in patients with bone marrow related problems.  Umbilical cord blood is a 
source of hematopeitic stem cells (Consolini et al., 2001;Wright-Kanuth and Smith, 
2001) and mesenchymal stem cells (Kogler et al., 2004;Sanberg et al., 2005). 
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Figure 1.1 H & E stained cross section of umbilical cord and morphology of umbilical 
cord matrix stem cells in a culture 
 
Multipotent stem cells called umbilical cord matrix stem (UCMS) cells are isolated 
from the umbilical cord matrix (Mitchell et al., 2003b).  Other labs have isolated 
multipotent mesenchymal stem cells from various parts of umbilical cord (Kogler et al., 
2004;Sarugaser et al., 2005a).  UCMS cells are postnatal cells and can be harvested 
non-invasively in large numbers.  The latter is particularly important since it has been 
estimated that a typical transplantation dose for human therapy is about a billion cells 
(Normile, 2007).  UCMS cells synthesize the three major proteins associated with the 
pluripotent state (Sox2, Nanog, and Oct4) (Carlin et al., 2006).  To test the safety of 
UCMS cells for transplantation studies, UCMS cells were transplanted in large numbers 
in SCID mice to assess possible teratoma or other tumor formation, as is sometimes the 
case with other primitive stem cells (Thomson and Marshall, 1998;Arnhold et al., 2004).  
No evidence of teratoma or other tumor was noted, indicating the cells are safe to use 
as drug delivery vehicles (Rachakatla et al., 2007).  Recent work demonstrated that 
UCMS cells transduced with recombinant fiber modified adenovirus containing IFN-β 
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can secrete sufficient IFN-β to kill MDA 231 cells in vitro.  In the in vivo studies involving 
MDA 231 breast carcinoma lung tumor models, UCMS cells administered systemically 
via the tail vein exhibited selective engraftment in the MDA 231 lung tumors of SCID 
mice.  Tumor burden was significantly reduced following systemic administration of 
human IFN-β-expressing UCMS cells into tumor-bearing SCID mice (Rachakatla et al., 
2007). 
TUMOR AND TUMOR MICROENVIRONMENT 
Tumors are sites of inflammatory cytokine and chemokine production (Hall et al., 
2007).  Apart from tumor cells themselves, tumors have a supportive, non tumor stroma.  
There are thought to be four major components of tumor stroma: 1) connective tissue 
matrix components; 2) vascular cells; 3) cells of the immune system; and 4) fibroblastic 
stromal cells (Hall et al., 2007). The latter have been designated as ‘tumor associated 
fibroblasts’ (TAF) (Kunz-Schughart and Knuechel, 2002a;Kunz-Schughart and 
Knuechel, 2002b), ‘carcinoma associated fibroblasts’ (CAF) (Orimo et al., 2005), or 
‘reactive stroma’ (Rowley, 1998;Hall et al., 2007). 
Bone marrow (BM) fibroblasts also play an important role in the development of 
stromal cell populations in tumors in mice (Direkze et al., 2004;Ishii et al., 2005).  
Fibroblast stromal cells secrete stromal derived factor 1 (SDF-1), which in turn promotes 
angiogenesis and tumor cell growth (Orimo et al., 2005).  Tumor-associated stromal 
cells produce factors such as cytokines, growth factors, and matrix-degrading enzymes 
that biologically impact the tumor microenvironment (Silzle et al., 2004). Several other 
chemokines are known to be secreted by tumors, including vascular endothelial growth 
factor (VEGF), transforming growth factor (TGF) family members, fibroblast growth 
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factor (FGF) family members, platelet derived growth factor (PDGF) family members, 
monocyte chemotactic protein -1 (MCP-1), epidermal growth factor (EGF), and 
interleukin-8 (IL-8) (Nakamura et al., 2004). 
Breast cancer cells have been reported to secrete the chemokines CXCR4, 
CCL5, and CCL2 (Muller et al., 2001;Kulbe et al., 2004).  SDF-1 is expressed in many 
tumor cells like breast, lung, pancreatic, colon, prostate, neuroblastoma, glioblastoma, 
and ovarian carcinomas (Koshiba et al., 2000;Rempel et al., 2000;Geminder et al., 
2001;Scotton et al., 2001;Muller et al., 2001;Schrader et al., 2002;Taichman et al., 
2002;Burger et al., 2003;Hwang et al., 2003;Zeelenberg et al., 2003).  While tumors 
secrete chemokine factors, they recruit stromal, vascular, bone marrow and other stem 
cells to the tumor; theoretically the recruited cells provide a scaffolding and source of 
nutrients (Tlsty and Hein, 2001;van Kempen et al., 2003;Kucerova et al., 2007).  
Presence of chemokine receptors on various cells may aid in trafficking of these 
cells toward tumors.  Low passage human bone marrow mesenchymal stem cells 
(MSC) have been shown to express the following chemokine receptors: CCR1, CCR7, 
CCR9, CXCR4, CXCR5, and CXCR6 (Honczarenko et al., 2006).  MSCs cultured in 
serum-free medium express a number of chemokine ligands (CCL2, CCL4, CCL5, 
CCL20, IL-8, IL-12, CXCL8, CXCL12, and CX3CL1) (Honczarenko et al., 2006).  
Factors such as SDF-1 alpha, EGF, and PDGF been shown to enhance bone marrow 
MSC migration to tumor cells (Nakamizo et al., 2005).  There is also abundant evidence 
that stem cells show tropism towards injured tissue or organ sites (Aboody et al., 
2000;Natsu et al., 2004;Rojas et al., 2005;Lange et al., 2005;Phinney and Isakova, 
2005;Sato et al., 2005;Silva et al., 2005), and can engraft and persist within tumor 
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microenvironments (Studeny et al., 2002;De et al., 2003;Studeny et al., 2004;Nakamizo 
et al., 2005;De et al., 2005;Rachakatla et al., 2007).  
GENE THERAPY 
During the last decade, gene therapy has become an emerging area of research 
in the medical and pharmaceutical field (Rawat et al., 2007).  Gene therapy can be 
defined as transfer of the new genetic material into an individual’s cells and tissues for 
therapeutic applications by altering function at cellular or molecular level (Goessler et 
al., 2006).  The therapeutic gene needs a carrier vector to deliver it to the target cells.  
Each vector has unique properties and various gene carrying vectors have been 
investigated for efficient intracellular delivery.  There are variety of vectors to deliver the 
genes to the target cells, such as viral vectors and non viral vectors.  The most common 
viral vector systems are retroviruses (Kohn et al., 1989;Gilboa, 1990;Cournoyer and 
Caskey, 1993), adenoviruses (Rowe et al., 1953;Ballay et al., 1985;Yamada et al., 
1985;Stewart et al., 1991;Lemarchand et al., 1992;Rosenfeld et al., 1992), adeno-
associated viruses (AAV) (Blacklow et al., 1968;Cheung et al., 1980;Podsakoff et al., 
1994), and herpes simplex viruses (Glorioso et al., 1995).  The non viral methods 
include cationic liposomes (Thierry and Dritschilo, 1992;Bennett et al., 1992;Ropert et 
al., 1993), direct injection of naked DNA plasmids (Zhang et al., 2001), electroporation 
(Magin-Lachmann et al., 2004), and antisense oligonucleotides (Thierry and Dritschilo, 
1992;Bennett et al., 1992). 
The characteristics of both viral and non viral gene delivery systems are 
summarized in Table 1.1 (Romano et al., 1999; Goessler et al., 2006).  
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 Vector
s 
Adva
ntages 
Disadva
ntages 
Retroviru
s 
• Long term expression 
• Only infect dividing 
cells 
• No toxic effect on 
infected cells 
• Large DNA inserts 
possible 
• Inflammatory/ immune 
response 
• Potential insertional 
mutagenesis 
• Relatively low 
transfection efficiency 
Adenovir
us  
• Infect dividing as well 
as non dividing cells 
• Relatively long term 
expression 
• No toxic effect on 
infected cells 
• Large DNA inserts 
possible 
• Inflammatory/ immune 
response 
• Lack of permanent 
expression 
• Complicated vector 
genome 
Adeno-
associated 
viruses 
• Infect dividing as well 
as non dividing cells 
• Relatively long term 
expression 
• No toxic effect on 
infected cells 
• Small DNA insert size 
• Inflammatory/ immune 
response 
• Lack of permanent 
expression 
• Complicated vector 
genome 
• Not well characterized 
Herpes 
simplex virus 
• Neurotropic 
• Large DNA inserts 
possible 
• Long term expression 
• Neurotropism limits use 
• Relatively low 
transfection efficiency 
• Potential wild type 
breakthrough 
Direct 
injection 
(naked 
DNA/ plasmids) 
• Technically simple 
• Non toxic 
• Local delivery  
• Infect dividing as well 
as non dividing cells 
• Unable to target specific 
cells 
• Relatively low 
transfection efficiency 
• Low long term 
transfection rates 
Electrop
oration  
• Nontoxic 
• Large DNA inserts 
possible 
• Infect dividing as well 
as non dividing cells 
• Unable to target specific 
cells 
• Need for electric 
impulses 
• Relatively low 
transfection efficiency 
• Complex equipment 
Liposom • Technically simple 
• Large DNA inserts 
• Unable to target specific 
cells 
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es  possible 
• Local delivery  
• Non immunogenic 
• Relatively low 
transfection efficiency 
• Low long term 
transfection rates 
Antisens
e 
oligonucleotides 
• Technically simple 
• Sequences can be 
ordered commercially 
• Nontoxic  
• Very short term 
• Not always successful 
in decreasing 
expression 
• Non specific  
 
Table 1.1  Summary of viral and non viral gene delivery systems 
 
  
Though the viral gene delivery systems are associated with an increased risk of 
virus-associated toxicity (Salyapongse et al., 1999), they have been engineered for 
safety by making them replication incompetent (Robbins and Ghivizzani, 1998).  
Retroviruses are used for ex vivo gene therapy applications only as they are not 
efficient in infecting non dividing cells (Danos and Heard, 1992;Robbins and Ghivizzani, 
1998).  Adeno-associated virus, adenovirus, herpes simplex virus, as well as the non 
viral vectors are efficient in infecting both diving and non dividing cells and are used for 
either direct in vivo or ex vivo delivery (Oligino et al., 2000).  
Non viral vectors are inexpensive and can be produced in large amounts. These 
vectors are safe and have a low immunogenicity (Oligino et al., 2000). However, the 
disadvantage of non viral vectors over viral vectors is that they have relatively low 
transfection efficiency (Salyapongse et al., 1999).  
POTENTIAL ROLE OF STEM CELLS IN HOMING AND GENE THERAPY 
Stem cells migrate toward wounds and other areas of pathology and have been 
shown to be effective gene-delivery vehicles for targeted cancer therapy (Aboody et al., 
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2000;Studeny et al., 2002;Brown et al., 2003;Studeny et al., 2004;Nakamura et al., 
2004;Natsu et al., 2004;Rojas et al., 2005).  The first report describing stem cell tropism 
for tumors involved NSCs; Aboody and colleagues reported that these stem cells had 
the ability to migrate to experimental intracranial gliomas (Aboody et al., 2000).  The 
authors have shown that NSCs implanted into intracranial gliomas established in mice, 
distributed themselves throughout the tumor mass, and infiltrated the tumor cells but 
were not seen in any other healthy brain tissue.  NSCs transplanted intracranially at 
distant sites from the tumor also migrated toward the tumors (Aboody et al., 2000).  
Cellular homing and migration of NSCs to tumor cells is affected by the expression of 
CXCR4, a chemokine receptor (Gupta et al., 1998;Muller et al., 2001;Schrader et al., 
2002;Lazarini et al., 2003).  
Genetic modification of stem cells has facilitated their use as drug delivery 
vehicles for antitumor compounds.  Several investigators have genetically modified 
NSCs with antitumor agents such as interleukin 12 (IL-12), interferon-γ, and tumor 
necrosis factor-related apoptosis inducing ligand (TRAIL).  When transplanted into 
glioma rodent models these modified cells increased the survival rates of the animals 
(Ehtesham et al., 2002a;Ehtesham et al., 2002b;Ehtesham et al., 2002c;Shah et al., 
2003;Yang et al., 2004;Shah et al., 2005).  Ehtesham et al. have infected NSCs with 
either adenoviral vector expressing the gene for murine IL-12 (AdmIL-12) or beta-
galactosidase (AdLacZ).  To determine the homing ability, NSCs infected with AdLacZ 
(NSC-LacZ) were injected into the contra- lateral corpus striatum 7 days after 
establishing intracranial glioma.  NSCs preferentially migrated towards the tumor mass, 
and did not migrate to adjacent normal tissue (Ehtesham et al., 2002b).  These authors 
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have also investigated the therapeutic ability of NSCs infected with AdmIL-12 (NSC-IL-
12).  For tumor inoculation, GL26 glioma cells were injected into the right corpus 
striatum, and 2 days later, NSC-IL-12 were injected directly into the established tumor.  
They found that NSC-IL-12 delayed the tumor growth and prolonged the survival period 
of tumor-bearing animals.  Nearly 30% of animals survived for more than 60 days after 
tumor implantation (Ehtesham et al., 2002b).  A similar study by Yang et al. showed that 
NSCs expressing IL-12 have a strong antitumor effect (Yang et al., 2004).  MRI studies 
showed that NSCs injected directly into the tumor gradually decreased the tumor in the 
tumor-bearing rats and the survival rate was significantly prolonged when compared to 
controls (Yang et al., 2004).  NSCs engineered with a retrovirus expressing cytosine 
deaminase (CD) were transplanted into intracranial glioma established in nude mice; 
following systemic treatment with pro drug, 5-fluorocytosine (5-FC).  Since CD 
metabolizes the relatively non toxic prodrug 5-FC to the highly toxic 5-fluorouracil (5-
FU), tumor burden was drastically reduced (80%) as compared with untreated animals.  
In vitro co-culture experiments of CD bearing NSCs and glioma cells in combination with 
5-FC significantly increased tumor cell death (Aboody et al., 2000).  In more recent 
studies, NSCs were infected with retrovirus expressing CD (CD-NSCs) and co-cultured 
CD-NSCs with medulloblastoma cells.  Following 5-FC treatment, the CD-NSCs 
inhibited the cancer cells significantly (Shimato et al., 2007).  These results were 
consistent with an in vivo leptomeningeal dissemination model, where CD-NSCs 
injected directly into cerebrospinal fluid migrated and engrafted into the tumor area and 
showed an antitumor effect after systemic injection of 5-FC (Shimato et al., 2007). 
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Bone marrow MSCs have been shown to exhibit a tropism for damaged or 
rapidly growing tissues as well as tumors (Azizi et al., 1998;Kopen et al., 1999;Studeny 
et al., 2002;Studeny et al., 2004;Nakamizo et al., 2005).  Bone marrow derived 
mesenchymal stem cell based gene therapies for cancer models have received 
considerable scrutiny in the last few years (Studeny et al., 2002;Lee et al., 2003;Zhang 
et al., 2004;Nakamura et al., 2004).  The bone marrow cells that adhere have good 
proliferating capacity and have been shown to contribute to stroma formation even in 
sites that are remote from bone marrow (Hamada et al., 2005).  The increased cell 
turnover triggered at the time of tissue damage or tumor growth may also help in the 
successful engraftment of MSC in tissues (Hall et al., 2007).  In vitro chemotaxis assay 
studies revealed that MSCs migrate in response to expression of SDF-1 and fractalkine 
(CX3CL1), a membrane-bound glycoprotein (Ji et al., 2004).  Magnetic resonance 
imaging (MRI) studies in experimental glioma rat models transplanted with neural 
progenitor cells and bone marrow MSCs either directly into the brain or intravenous 
injections showed extensive migration of MSCs towards tumor mass and infiltrated 
tumor cells (Zhang et al., 2004).  Several viral vectors have been used to deliver 
transgenes into MSCs. 
Nakamura et al. have reported that MSCs transduced with recombinant 
adenovirus expressing interleukin-2 (IL-2), when transplanted into glioma-bearing rats 
showed tropism to tumors, reduced the tumor burden, and prolonged the survival of the 
rats (Nakamura et al., 2004;Hamada et al., 2005).  In similar experiments, MSCs 
transduced with adenovirus IL-2 and injected into tumor bearing mice have increased 
the immune response (CD8 mediated tumor specific immunity) and significantly delayed 
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tumor growth when transplanted into a B16 melanoma mouse model (Stagg et al., 
2004). 
An example of a protein successfully delivered via stem cells for an anti-tumor 
effect is interferon beta (IFN-β) (Studeny et al., 2002;Studeny et al., 2004).  This 
cytokine has potent pro-apoptotic (Lokshin et al., 1995;Chawla-Sarkar et al., 2001) and 
antiproliferative (Wong et al., 1989;Johns et al., 1992) effects in vitro.  However, IFN-β 
alone often cannot be used effectively as cancer therapy because of its excessive 
toxicity when administered systemically at high doses (Salmon et al., 1996;Einhorn and 
Grander, 1996;Buchwalder et al., 2000), and moreover it has a short half-life.  Studeny 
et al. have shown that high toxicity can be reduced by transplanting MSCs infected with 
adenovirus expressing IFN-β (MSC-IFN-β) to tumors. A SCID mouse model bearing 
MDA 231 lung tumors was used to examine the effects of recombinant IFN-β on the 
growth of the tumors and their survival in vivo.  Tumor bearing mice injected with MSC-
IFN-β cells contributed to stroma formation and prolonged the survival of mice when 
compared to untreated mice.  The survival was prolonged due to the suppression of 
tumor growth by MSC-IFN-β cells, through the local production of IFN-β in the tumor 
microenvironment.  Mice injected with recombinant human IFN-β did not prolong the 
survival of the tumor bearing mice.  The same report showed that co-cultures of MSC-
IFN-β cells with MDA 231 breast carcinoma cells and A375SM melanoma cells inhibited 
the tumor cell growth when compared to growth of tumor cells cultured alone (Studeny 
et al., 2004).  Thus stem cells can be used as a platform for targeted delivery of 
therapeutic proteins to the cancer sites. 
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Abstract 
Adenovirus vectors have the ability to transduce both dividing and non dividing 
cells.  However, most adenoviruses can transduce successfully only those cells that 
express Coxsackie-Adenovirus Receptor (CAR) and αvβ3 and αvβ5 integrins.  Efficient 
adenoviral (Ad5) transduction depends on binding of the fiber protein of the virus to the 
CAR, and their subsequent internalization, mediated by viral penton base binding with 
target cell integrins.  On the other hand, fiber-modified adenovirus can be effective in 
overcoming these limitations; CAR independent targeting strategies, such as fiber-
modification with variable lengths of polylysine (K4, K7 and K21).  In this study, we 
compared the transduction efficiency in human umbilical cord matrix stem (UCMS) cells 
by wild type and fiber-modified adenoviruses.  UCMS cells are derived from Wharton’s 
jelly found between the vessels of umbilical cord.  To compare the transduction 
efficiency, UCMS cells were transduced with either wild type (Ad5) or fiber-modified 
adenovirus (Ad5/K4, Ad5/K7, Ad5/K21) beta galactocidase (β-Gal).  All the fiber-
modified adenoviruses transduced UCMS cells more efficiently when compared to wild 
type adenovirus.  These results suggest that the fiber-modified viruses will help in 
designing safer gene therapy methods and can achieve higher clinical efficacy when 
compared with wild type adenoviruses. 
 
Introduction 
Recombinant adenoviral vectors are used most commonly for in vitro and in vivo 
gene therapeutic experiments in numerous gene transfer studies.  Adenovirus vectors 
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have the remarkable ability of transducing not only the quiescent (or dormant) cells but 
also the rapidly proliferating cells (Kovesdi et al., 1997;Benihoud et al., 1999). However, 
most prevalently used adenovirus can transduce successfully only in those cells that 
express Coxsackie-Adenovirus Receptor (CAR) (Bergelson et al., 1997;Tomko et al., 
1997;Bergelson et al., 1998) and αvβ3 and αvβ5 integrins (Wickham et al., 1993;Huang 
et al., 1996).  The adenovirus infection of the target cells involves two unique steps.  
The first step is the binding of the C terminal knob domain of fiber protein of the virus to 
the CAR on the surface of the target cells (Bergelson et al., 1997;Tomko et al., 1997).  
Following that, the RGD (Arg-Gly-Asp) motif of the penton bases bind to αvβ3 and αvβ5 
integrins, expressed on most cell types.  These interactions enable the internalization of 
the virus in the target cells via receptor mediated endocytosis (Wickham et al., 
1993;Wickham et al., 1994).  Since the presence of CAR is the first determinant of 
adenoviral infection, the interaction of the fiber knob with CAR on the cell is the 
important factor for the entry of the adenovirus into the cell. 
However, the adenoviral vector mediated gene transfer is limited due to the 
absence or extremely low expression of CAR in certain kinds of cells, including 
differentiated airway epithelium, skeletal muscle cells, smooth muscle cells, peripheral 
blood cells, hematopoietic stem cells and most mouse derived cells (Mentel et al., 
1997;Marini et al., 1999;Wickham, 2000;Rebel et al., 2000).  If the cells are transduced 
with high multiplicities of infection (MOIs) or stimulated by numerous other growth 
factors,  then the stem cell infection can be achieved with adenovirus serotype 5 (Ad5) 
(Mackenzie et al., 2000). However these may induce differentiation of the cells and loss 
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of the most pluripotent population (Mackenzie et al., 2000) and following infection there 
may be a high proportion of cell death (Mackenzie et al., 2000).  
The limitation imposed by the expression of CAR in the target cells for 
adenovirus infection can be potentially overcome by modifying the adenovirus fiber 
protein.  One of the many promising strategies to overcome this limitation, involves 
addition of foreign peptides to the H1 loop or C terminus of the fiber knob, such as 
mutant fiber proteins containing RGD peptides (Wickham et al., 1997;Dmitriev et al., 
1998;Krasnykh et al., 1998;Hidaka et al., 1999;Koizumi et al., 2001;Mizuguchi et al., 
2001) or polylysine repeats (K3, K7, K21) (Wickham et al., 1997;Hidaka et al., 
1999;Bouri et al., 1999;Gonzalez et al., 1999b).  Nevertheless, modification of Ad5 knob 
fiber tropism forms the basis for the transduction of normal and hemotopoietic cells 
(Yotnda et al., 2001;Yotnda et al., 2004), it is still unclear whether fiber-modified virus 
will prove optimal for umbilical cord matrix stem (UCMS) cells.  
UCMS cells are derived from Wharton’s jelly found between the vessels of 
umbilical cord and have been shown to have properties similar to bone marrow-derived 
mesenchymal stem cells (Weiss et al., 2006). They can be isolated in large numbers in 
a short time and thus potentially represent an abundant source of cells for therapeutic 
use.  
Here, we have compared the transduction efficiency in human UCMS by wild 
type Ad5 and fiber-modified viruses.  We determined which vectors transduced the 
highest percentage of cells with lowest viral particle to cell ratio and compared their 
levels of expression. 
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Material and methods 
Cell culture and antibodies 
Human umbilical cord matrix stem (UCMS) cells were harvested from term 
deliveries at the time of birth with the mother‘s consent.  The methods to isolate and 
culture human UCMS cells were previously described (Weiss et al., 2006).  Human 
UCMS cells were maintained in defined medium (DM) (Weiss et al., 2006). 
Rabbit anti β-Gal polyclonal antibody was purchased from Becton Dickinson, NJ) 
and Alexa Fluor 488 conjugated secondary antibody was purchased from Molecular 
Probes, CA. 
Adenoviral transduction of human UCMS cells with wild type and fiber-
modified β-Gal adenoviruses  
Human UCMS cells were transduced with either wild type or fiber-modified β-Gal 
recombinant adenovirus (Studeny et al., 2002).  For transduction, UCMS cells were 
plated at 50,000 cells per well in a 12-well plate and twenty four hours later, the human 
UCMS cells were washed twice with DMEM without serum and cells were incubated 
with DMEM containing either wild type (Ad5) or fiber-modified (Ad5/K4, Ad5/K7, 
Ad5/K21) adenovirus β-Gal at various amounts (50, 100, 200, 400, 800, 1600, 3200, 
6400, 12500, 25000 and 50000) of adenoviral particles (VP) per cell for 4 hours at 37oC.  
Medium containing 5% FBS was added after incubation.  Production of β-Gal protein 
was determined 48 hours after transduction, using immunocytochemistry.  
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Immunocytochemistry 
For immunofluorescence staining, β-Gal transduced UCMS cells were fixed by 
treating with buffered neutral formalin (BNF).  This was followed by washing the fixed 
cells with three changes of phosphate buffered saline-0.2% Triton X-100 (PBS-TX).  The 
cells were blocked with 5% normal goat serum in PBS-TX for 30 minutes, and later 
incubated with primary antibody, anti-rabbit β-Gal antibody (1:1000 Becton, Dickinson, 
NJ), in PBS-TX for 60 min.  The cells were then washed three times with PBS-TX and 
incubated with Alexa Fluor 488 conjugated secondary antibody (1:1000, Molecular 
Probes, CA) for 45 minutes.  The antigens were localized using epifluorescence 
microscopy (Nikon Eclipse) and images were captured using a Roper Cool Snap ES 
camera and Metamorph 7. 
Results 
Effect of transduction efficiency of wild type and fiber-modified adenovirus 
β-Gal in human UCMS cells  
To investigate the efficiency of gene transfer of wild type and fiber-modified 
viruses in human UCMS cells, we transduced UCMS cells with either wild type or fiber-
modified adenoviruses β-Gal.  Forty eight hours after infection, the cells were analyzed 
by immunocytochemistry for β-Gal expression.   
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Figure 2.1 Adenoviral mediated expression of β-Gal. 
Human UCMS cells transduced with fiber-modified β-Gal adenoviruses and 
immunostained with anti β-Gal antibody (green). A. Ad5/K4: B. Ad5/K7: C. Ad5/K21.   
  
The expression β-Gal in UCMS cells was confirmed by immunocytochemistry 
(Figure 2.1).  Ad5/K4 mediated gene transfer was the most efficient, with a maximum of 
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100% positive expression when transduced with 200 VP/cell (Figure 2.2).  Ad5/K7 
mediated gene transfer of UCMS cells was 100% when transduced with 800 VP/cell 
and Ad5/K21 mediated gene transfer was 100% at 6400 VP/cell transduction (Figures 
2.3 and 2.4).  Wild type adenovirus resulted in negligible transduction regardless of 
dose of VP/cell (no expression even at 50000 VP/cell).  These results suggest that 
transduction efficiency of fiber-modified adenoviruses were very effective when 
compared with wild type adenoviruses in human UCMS cells. 
 
 
Figure 2.2  Human UCMS cells transduced with Ad5/K4. 
The maximum expression was obtained with 200 VP per cell.  The data are represented 
as mean ± standard deviation (SD) on graphs. 
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Figure 2.3  Human UCMS cells transduced with Ad5/K7. 
The maximum expression was obtained with 800 VP per cell.  The data are represented 
as mean ± SD on graphs. 
 
Figure 2.4  Human UCMS cells transduced with Ad5/K21. 
The maximum expression was obtained with 6400 VP per cell.  The data were 
represented as mean ± SD on graphs. 
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Discussion 
The characteristic of Ad5 to transduce either quiescent or proliferating cells and 
to produce a high level of transient gene expression makes it an indispensable vector 
for gene therapeutic protocols.  However this virus works inadequately in many types of 
cells because they lack necessary receptor molecules for binding (CAR) (Bergelson et 
al., 1997) and for internalization (integrins) (Wickham et al., 1993).  
There have been other strategies to infect normal and malignant cells of the 
hematopoietic lineage including the usage of lipofectamine (Byk et al., 1998), bi specific 
antibodies that target both adenovirus epitopes and cell antigens, biotinylated 
adenoviruses (Smith et al., 1999), or adenoviruses with heparin sulfate binding domains 
(Gonzalez et al., 1999a).  In all these studies, it has been generally observed that large 
amounts of vector were needed and that there has not been much proven success with 
highly primitive stem cell populations (Smith et al., 1999;Gonzalez et al., 1999a).  
Several studies have shown a way to overcome these restrictions with the use of fiber-
modified adenovectors (Yotnda et al., 2001;Yotnda et al., 2004).  The limitations of the 
other alternatives available for this application made us concentrate on adenovectors.  
Retroviruses have shown to be integrating vectors, and may intensify the cellular 
dysfunction in already stable cells (Li et al., 2002).  Lentiviral vectors were used in the 
transfection of quiescent human acute lymphoblastic leukemia and acute myeloid 
leukemia cells, but the productivity is minimal and may require co-culturing with stroma 
and/or cytokines (Biagi et al., 2001) whereas the adenovectors have the abilities to 
transduce non dividing cells, are non integrating, and provide high levels of transgene 
expression.   
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Since this study was done to compare the efficiency of transduction, we 
standardized infection in terms of number of viral particles per cell, duration, and 
temperature of transduction (4 hr 37oC).  Of the vectors tested, the modified Ad/K4 
consistently transduced up to 100% of UCMS cells at a low viral particle to cell ratio and 
thus constitutes the most efficient of the vectors that were under study. 
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Abstract 
Umbilical cord matrix stem (UCMS) cells are derived from mesenchyme-like 
cushioning material called ‘Wharton’s jelly’ found between the vessels of the umbilical 
cord.  The umbilical cord matrix contains an inexhaustible, non-controversial source of 
stem cells.  Chemokines control immune and inflammatory cellular migration and play 
an important role in tumor progression.  In this study, we examined the role of MDA 231 
human breast carcinoma cells and some chemokines in trafficking of human UCMS 
cells in an in vitro model of cell migration.  To investigate the migratory nature of human 
UCMS cells towards MDA 231 cells, UCMS cells were cultured with or without MDA 231 
cells for 24 hours.  UCMS cells were found to migrate in a dose dependent manner with 
an increasing number of MDA 231 cells.  Next, we evaluated the effect of two candidate 
chemokines, SDF-1 and VEGF, on human UCMS cells by challenging them with 
increasing doses of the two factors.  Both SDF-1 and VEGF increased the migration of 
UCMS cells in a dose dependent manner.  Because the UCMS cells respond positively 
to SDF-1 and VEGF , these factors may be involved in the in vivo trafficking of the stem 
cells to MDA 231 metastatic lung tumors.  Within the tumor, cancer cells or cancer-
associated stromal cells might be releasing chemokine factors such as SDF-1 and 
VEGF which promote UCMS cell migration towards the tumor cells in vitro.  Since the 
UCMS cells respond to chemotactic signals from tumors, they can be used as gene 
delivery vehicles in targeting the tumors in vivo. 
Introduction 
The umbilical cord contains an inexhaustible, non-controversial source of stem 
cells.  Worldwide, millions of umbilical cords, each containing millions of stem cells, are 
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routinely discarded after birth.  Multipotent stem cells called umbilical cord matrix stem 
(UCMS) cells are isolated from the mesenchyme-like cushioning material ‘Wharton’s 
jelly’ found between the vessels of the umbilical cord (Mitchell et al., 2003).  These cells 
resemble stem cells from several other sources but are also unique in some properties.  
Several characteristics argue for their potential use in cell-based therapeutic solutions 
for human or animal diseases: Large numbers of cells that can be isolated from a single 
umbilical cord, the noninvasive postnatal (hence, non-controversial) harvest of cells, 
and the inexhaustible supply of umbilical cords (Weiss et al., 2006;Karahuseyinoglu et 
al., 2007).  Thus, they may offer an immediate avenue for cytotherapy, when time is of 
the essence for such therapy, for example in cases of malignant neoplasia. 
Tumors are sites of inflammatory cytokine and chemokine production (Hall et al., 
2007).  Chemokines are low molecular weight proteins secreted by cells and 
characteristically have four conserved cysteine residues.  They are pro-inflammatory, 
play an important role in leukocyte maturation, trafficking, angiogenesis, migration of 
cells during tissue development, and in homing of T and B lymphocytes (Taub and 
Oppenheim, 1994;Bokoch, 1995;Premack and Schall, 1996;Luster, 1998).  Chemokines 
are classified into four sub families based on spacing of their first two cysteine residues; 
α-chemokines (CXC), β-chemokines (CC), γ-chemokines (C) and δ–chemokines 
(CXXXC) (Taub and Oppenheim, 1994;Bokoch, 1995;Premack and Schall, 1996;Luster, 
1998).  Stromal cell-derived factor 1a (SDF-1) is a member of the α-chemokine 
subfamily and its cognate receptor is CXCR4 (Hamada et al., 1996;Feng et al., 
1996;Smith et al., 2004).  CXCR4 expression was observed to be upregulated in 
glioblastomas and breast cancer cells (Sehgal et al., 1998;Muller et al., 2001;Kulbe et 
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al., 2004).  SDF-1 plays an important role in homing as shown by studies on 
engraftment of hematopoietic stem cells to bone marrow (Peled et al., 1999) and 
engraftment of metastatic breast and prostate cancer cells to bone and bone marrow 
(Muller et al., 2001).  Vascular endothelial growth factor (VEGF) which belongs to the 
PDGF family, is a signaling protein involved in both vasculogenesis and angiogenesis 
(Ferrara and Gerber, 2001).  Active angiogenesis is a major hallmark of tumors 
(Harrigan, 2003).  Schmidt et al have shown that VEGF is responsible for migration of 
neural stem cells (NSCs) to distant sites in brain tumors (Schmidt et al., 2005). 
Tumor tropism is known to be mediated by cytokines, including VEGF, TGF 
family members, FGF family members, PDGF family members, MCP-1, EGF, and 
interleukin-8 (Nakamura et al., 2004).  Several investigators have shown that tumors, by 
secreting chemokine factors, recruit stromal, vascular, bone marrow and other stem 
cells to the tumor; theoretically the recruited cells provide a scaffolding and source of 
nutrients (Tlsty and Hein, 2001;van Kempen et al., 2003;Kucerova et al., 2007).  There 
has been abundant evidence that mesenchymal stem cells (MSC) show tropism 
towards injured tissue or organ sites (Natsu et al., 2004;Rojas et al., 2005;Lange et al., 
2005;Phinney and Isakova, 2005;Sato et al., 2005;Silva et al., 2005), and can engraft 
and persist within tumor microenvironments (Studeny et al., 2002;De et al., 
2003;Studeny et al., 2004;Nakamizo et al., 2005;De et al., 2005;Rachakatla et al., 
2007).  The chemokines, such as SDF-1 alpha, EGF, and PDGF were shown to 
enhance bone marrow MSC migration to tumor cells (Nakamizo et al., 2005). 
In vitro chemotaxis assay studies revealed that MSCs migrate in response to 
expression of SDF-1 and fractalkine (CX3CL1), a membrane-bound glycoprotein (Ji et 
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al., 2004).  Several other studies have shown that cellular homing and migration of 
NSCs to tumor cells is affected by the expression of CXCR4, a chemokine receptor 
(Gupta et al., 1998;Muller et al., 2001;Schrader et al., 2002;Lazarini et al., 2003).  Cell 
invasion assays using adipose tissue-derived mesenchymal stem cells (AT-MSC) have 
shown that these cells also have tropism towards tumor cells (Kucerova et al., 2007).  
Schmidt et al verified in vitro that tumor cells upregulated VEGF and recombinant VEGF 
stimulated NSC migration in a dose dependent manner (Schmidt et al., 2005). 
In the present study, we investigated migratory ability of human UCMS cells 
towards MDA 231 human breast carcinoma cells.  Next, we examined the effect of 
chemokines, SDF-1 and VEGF, on the migration of human UCMS cells.  Here, we show 
that human UCMS cells migrate towards MDA 231 cells in a dose dependent manner 
and there was a significant stimulatory effect of recombinant SDF-1 and VEGF on 
UCMS cell migration. 
Methods 
Cells and chemokines 
Human umbilical cord matrix stem (UCMS) cells were harvested from term 
deliveries with the mother‘s consent.  The methods to isolate and culture human UCMS 
cells were previously described (Weiss et al., 2006).  Human UCMS cells were 
maintained in low serum medium (LSM), a mixture of 56% low glucose Dulbecco's 
Modified Eagle's Medium (DMEM) (Invitrogen), 37% MCBD 201 (Sigma; St. Louis, MO ) 
and 2% fetal bovine serum (FBS, Atlanta Biologicals Inc, Georgia) containing 1x insulin-
transferrin-selenium-X (ITS-X, Invitrogen, CA), 1x ALBUMax1 (Invitrogen, CA), 1x Pen 
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/Strep (Invitrogen, CA), 10nM dexamethasone (Sigma, MO), 100μM ascorbic acid 2-
phosphate (Sigma, MO), 10ng/ml epidermal growth factor (EGF, R&D systems, 
Minneapolis), and 10ng/ml platelet derived growth factor-BB (PDGF-BB, R&D systems, 
MN), at 37oC in a humidified atmosphere containing 5% carbon dioxide.  Human UCMS 
cells were labeled with the fluorescent dye SP-DiI (Molecular Probes, CA) to a final 
concentration of 10µg/ml of culture medium (Rachakatla et al., 2007), prior to the cell 
migration assay.  MDA 231 human breast carcinoma cells were obtained from M.D. 
Anderson Cancer Center (Houston, TX) (Studeny et al., 2002).  They were maintained 
in DMEM (Invitrogen, CA), 1x Pen/Strep (Invitrogen, CA), and 10% FBS (Atlanta 
Biologicals Inc, GA), at 37oC in a humidified atmosphere containing 5% carbon dioxide. 
Recombinant murine stromal cell-derived factor-1 (SDF-1) and murine vascular 
endothelial growth factor (VEGF) were purchased from Peprotech Inc. (Rock Hill, NJ). 
Transduction of human UCMS cells with adenovirus expressing human 
interferon beta (IFN-β) 
Successful in vivo gene therapy using stem cells depends on delivery of 
therapeutic agents to suitable targeted cells; for this reason we investigated whether 
transgene expression (IFN-β) might have an effect on the migration and homing ability 
of UCMS cells.  UCMS cells were transduced using fiber-modified IFN-β recombinant 
adenovirus (Studeny et al., 2002).  For transduction, the human UCMS cells were 
washed twice with DMEM without serum and cells were incubated with DMEM 
containing adenovirus at 100,000 plaque forming units (PFU) per cell for 4 hours at 
37oC.  Medium containing 5% FBS was added after incubation and the UCMS-IFN-β 
cells were used for in vitro experiments the next day. 
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In vitro transwell cell migration assay 
The cell migration assay was performed using 24-well double chamber culture 
plates, Transwell (Corning, NY).  MDA 231 cells at various concentrations (50,000, 
100,000 and 500,000 cells) were loaded in the lower chambers of the 24-well culture 
plates.  24 hours following the initial plating of MDA 231 cells, the media was changed 
and replaced with serum free medium (DMEM).  Later, SP-DiI labeled human UCMS 
cells (1x 105 cells) cultured overnight were washed three times with DMEM and 
resuspended in DMEM and plated on the 8μm pore size inserts of the upper chamber 
and incubated for 24 hours at 370C in a humidified atmosphere containing 5% carbon 
dioxide.  Each condition was run in duplicate and was repeated at least thrice.  Results 
were evaluated by directly counting the number of migrated cells in each lower chamber 
using epifluorescence microscopy (Nikon Eclipse).  Similar experiments were carried out 
using IFN-β engineered human UCMS cells.  All data are presented as mean ± 
standard error on graphs. 
To assess the individual effects of various chemokines, such as SDF-1 and 
VEGF in cell migration, experiments were carried out using increasing doses of 
chemokines (10, 100, 250, and 500ng/ml) in DMEM.  The transwell membranes were 
coated with 25μg/ml of matrigel (Collabarative Biomedical products, MA) (Son et al., 
2006).  Media with various concentrations of chemokines was placed in lower chambers 
of the 24-well culture plates.  Human UCMS cells (1x 105 cells) were suspended in 
DMEM with or without chemokines (SDF-1 or VEGF) and were plated on to the upper 
chambers and incubated for 24 hours.  After incubation, the cells were scraped from 
upper surface of the membranes.  The membrane was then fixed and stained using 
 48
hematoxylin.  Once dry, the cells that migrated to the lower surface of the membrane 
were evaluated by directly counting from each transwell insert.  Experiments were 
repeated thrice with similar results. 
Statistical analysis 
The means of the experimental groups were evaluated to confirm that they met 
the normality assumption.  To evaluate the significance of overall differences in all in 
vitro groups, statistical analysis was performed with the student’s t-test.  A p-value less 
than 0.05 was considered as significant.  All the data were represented as mean ± 
standard error on graphs.  Statistical analyses were performed by Stat View software, 
version 5.0.1. (Cary, NC). 
Results 
In vitro migratory potential of human UCMS cells 
The ability of human UCMS cells to migrate toward MDA 231 cells was evaluated 
by an in vitro cell migration assay model, where the SP-DiI loaded UCMS cells and 
MDA 231 cells are placed in the upper and lower chambers respectively in a double 
chamber Transwell culture plate and incubated for 24 hours.  Lower chambers 
containing either DMEM with 10% FBS or DMEM with no MDA 231 cells served as 
positive and negative controls.  Directional migration of human UCMS cells was 
significantly stimulated by either MDA 231 cells or DMEM with 10% FBS when 
compared with controls (DMEM and no MDA 231 cells)(Figure 3.1).  Notably, migratory 
ability of UCMS cells increased in a dose dependent manner with increasing number of 
MDA 231 cells. 
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Figure 3.1  In vitro migration effect of UCMS cells toward MDA 231 human breast 
carcinoma cells.   
UCMS cell migration increased in a dose dependent manner with increasing number of 
MDA 231 cells in the lower chamber.  * Statistically significant (p-value less than 0.05). 
Migration of human UCMS cells was not affected by transgene (IFN-
β expression) 
To investigate the migratory nature of UCMS-IFN-β cells towards MDA 231 cells, 
similar experiments were performed as mentioned above and the cells were replaced 
with UCMS-IFN-β cells and incubated for 24 hours.  The number of cells migrated to the 
lower chamber increased in a dose dependent manner with increasing numbers of MDA 
231 cells and there was significant difference (P<0.05) when compared with controls 
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(data not shown).  Thus, engineering with IFN-β did not impair the migration capability 
ability of UCMS cells. 
Effect of chemokines on migration of human UCMS cells  
We hypothesized that the migration of human UCMS cells towards MDA 231 
cells was due to several chemokines released by the MDA 231 cells.  Therefore we 
evaluated the effect of the chemokine SDF-1, and VEGF on UCMS cell migration.  The 
chemotactic effect of VEGF was increased in dose dependent manner and there was 
significant increase in UCMS cell migration when VEGF was added to DMEM in the 
lower chamber when compared to control (DMEM with out VEGF) (Figure 3.2).  Similar 
chemotactic effect was observed when SDF-1 was added to DMEM in lower chamber.  
There was significant increase in UCMS cell migration when SDF-1 was added when 
compared with control (DMEM without SDF-1) (Figure 3.2).  We also looked at the 
migratory ability of UCMS cells, when either SDF-1 or VEGF was added in both upper 
and lower chambers of the transwell plates and we observed that the UCMS cell 
migration was not significant enough when compared to control (DMEM alone).  These 
results showed that VEGF and SDF-1 were significant and there may be several other 
chemokines along with these chemokines which may be responsible for the migratory 
effect of UCMS cells towards MDA 231 cells. 
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Figure 3.2  In vitro migration effect of UCMS cells toward chemokines (SDF-1 and 
VEGF). 
UCMS cell migration increased in a dose dependent manner with dose of chemokine in 
the lower chamber.  * Statistically significant (p-value less than 0.05). 
Discussion 
The understanding of the mechanism of chemokines that regulates migration of 
human UCMS cells is crucial for future clinical studies.  Here, we address the migratory 
ability of human UCMS cells in response to chemokines and MDA 231 cells.  In our in 
vitro study, we showed that MDA 231 cells were able to attract human UCMS cells in a 
dose dependent manner, and this activation and migration of UCMS cells may be 
mediated by chemokines released into the media by MDA 231 cells.  Moreover, in vitro 
studies showed that UCMS cells migrated and responded in a dose dependant manner 
SDF-1 and VEGF.   
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Human UCMS cells have been characterized by gene array and cytokine array 
and they were found to express chemokine receptors including SDFR1, TGFBR3, 
FGFR2 (Weiss et al., 2006).  The finding that human UCMS cells express these 
receptors is in agreement with the migration of human UCMS cells to these 
chemokines.  Although the SDF-1-CXCR4 system contributed to UCMS cell migration, it 
is unclear whether those receptors operate synergistically or if they act in response to 
distinct stimuli.  Several other studies have reported that homing and differentiation of 
neural precursors in the adult brain are associated with active angiogenesis, where in 
VEGF acts as a chemo attractant (Louissaint, Jr. et al., 2002;Monje et al., 2002;Zhang 
et al., 2003).  To our knowledge this is the first report showing in vitro chemotactic 
migration of human UCMS cells. 
In our earlier studies, human UCMS cells have been shown to migrate in vivo to 
tumors in response to chemotactic signals released by the tumors (Rachakatla et al., 
2007).  There may be more than one migratory stimulus for human UCMS cells, 
therefore UCMS cells can be mobilized to tumor tissue naturally or induced to migrate to 
the tumor tissue.  The possible candidates other than SDF-1 and VEGF may be 
cytokines such as transforming growth factor (TGF),  fibroblast growth factor (FGF), 
platelet derived growth factor (PDGF), monocyte chemoattractat protein-1, and IL-8 
released from tumor or inflammatory tissue (Hellstrom et al., 1999;Tille and Pepper, 
2002;Wang et al., 2002a;Wang et al., 2002b;Yu et al., 2003).  These factors released 
from cancer cells and/or associated stromal cells have been shown to promote 
migration of endothelial cell and stromal cell progenitors from the bone marrow towards 
the cancer tissue (Coussens and Werb, 2002;De et al., 2003), enhancing the formation 
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of tumor stroma (Weaver et al., 1996).  Similar mechanisms would be anticipated for 
migration of human UCMS cells in vitro towards tumor cells. 
The data presented here provide conclusive evidence that human UCMS cells 
can migrate to specific chemokine gradients of SDF-1, VEGF and to MDA 231 released 
chemokines.  Strategies to increase the functional expression of the chemokine 
receptors may be required to improve the further homing ability of UCMS cells to 
tumors. 
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Abstract 
Umbilical cord matrix stem (UCMS) cells are unique stem cells derived from 
Wharton’s jelly that have been shown to express genes characteristic of primitive stem 
cells.  To test the safety of these cells, human UCMS cells were injected both 
intravenously and subcutaneously in large numbers into SCID mice and multiple tissues 
were examined for evidence of tumor formation.  UCMS cells did not form gross or 
histological teratomas up to 50 days after post transplantation.  Next, to evaluate 
whether UCMS cells could selectively engraft in xenotransplanted tumors, MDA 231 
cells were intravenously transplanted into SCID mice, followed by intravenous 
transplantation of UCMS cells one and two weeks later.  UCMS cells were found near or 
within lung tumors but not in other tissues.  Finally, UCMS cells were engineered to 
express human interferon beta–designated “UCMS−IFN-β”.  UCMS−IFN-β cells were 
intravenously transplanted at multiple intervals into SCID mice bearing MDA 231 tumors 
and their effect on tumors was examined.  UCMS−IFN-β cells significantly reduced MDA 
231 tumor burden in SCID mouse lungs indicated by wet weight.  These results clearly 
indicate safety and usability of UCMS cells in cancer gene therapy.  Thus, UCMS cells 
can potentially be used for targeted delivery of cancer therapeutics. 
 
Abbreviations: 
UCMS cells, umbilical cord matrix stem cells; UCMS−IFN-β cells, interferon beta-
expressing UCMS cells; ESCs, embryonic stem cells; IFN-β, interferon beta; SCID, 
severe combined immunodeficiency; DMEM, Dulbecco's modified eagle's medium; 
FBS, fetal bovine serum; DMSO, dimethylsulphoxide; PBS, phosphate buffered saline; 
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SP-DiI, sulfonated derivatives of Dialkyl indol dye; HEPA, high efficiency particulate air;  
EDTA, ethylenediaminetetraacetic acid; IACUC, institutional animal care and use 
committees; IBC, institutional biosafety committee. 
Introduction 
The umbilical cord contains an inexhaustible, non-controversial source of stem 
cells.  Worldwide, millions of umbilical cords, each containing millions of stem cells, are 
routinely discarded after birth.  Multipotent stem cells called umbilical cord matrix stem 
(UCMS) cells are isolated from the mesenchyme-like cushioning material called 
‘Wharton’s jelly’ found between the vessels of the umbilical cord (Mitchell et al., 2003).  
These cells resemble stem cells from several other sources but are also unique in some 
properties.  The properties that promote their potential utility are the large number of 
cells recoverable from the umbilical cord, the noninvasive harvest following birth, and 
the abundant supply of umbilical cords (Weiss et al., 2006;Karahuseyinoglu et al., 
2007).  Thus, they may offer an immediate avenue for cytotherapy, when time is of the 
essence for such therapy, for example in cases of malignant neoplasia.  UCMS cells 
have been transplanted into rodent neurodegenerative models (Weiss et al., 
2003;Medicetty et al., 2004;Fu et al., 2006), have been extensively characterized 
(Weiss et al., 2006) and they express many of the genes expressed by primitive stem 
cells such as embryonic stem cells (ESCs) (Carlin et al., 2006).  They can be 
differentiated into a variety of cell types including muscle (Conconi et al., 2006), 
cartilage (Wang et al., 2004), bone (Wang et al., 2004), neural (Mitchell et al., 2003) 
cells and have been used for tissue engineered artificial blood vessels and heart valves 
(Hoerstrup et al., 2002). 
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Previously, several types of stem cells have been shown to migrate selectively 
into tumors (Aboody et al., 2000;Studeny et al., 2002).  Moreover, they have been 
engineered to secrete anti-tumor proteins, such as interferon beta (IFN-β), into the 
tumor microenvironment with favorable therapeutic effects in rodent animal models 
(Aboody et al., 2000;Studeny et al., 2002;Brown et al., 2003;Studeny et al., 
2004;Nakamizo et al., 2005).  In these cases, millions of stem cells have been 
transplanted systemically.  However, similar approaches in humans will likely require an 
order of magnitude more cells to achieve a comparable effect.  Since large numbers of 
UCMS cells can be obtained in a short time, they potentially could be a solution to this 
dilemma. 
An example of a protein successfully delivered via stem cells for an anti-tumor 
effect is interferon beta (IFN-β)(Studeny et al., 2002;Studeny et al., 2004).  This 
cytokine has potent pro-apoptotic (Lokshin et al., 1995;Chawla-Sarkar et al., 2001) and 
antiproliferative (Wong et al., 1989;Johns et al., 1992) effects in vitro.  Although gene 
therapy using bone marrow- or neural stem cells has been successful in treating cancer 
mouse models, the preparation of these stem cells usually requires complex methods 
and a relatively long time.  
In the present study, we investigated a key safety issue by transplanting large 
numbers of UCMS cells into SCID mice to assess possible teratoma or other tumor 
formation.  Next, we tested UCMS cells for their ability to selectively engraft in lung 
tumors of SCID mice.  Finally, we investigated whether UCMS cells, engineered to 
secrete IFN-β, could reduce lung tumor burden in SCID mice.  We show here that 
UCMS cells themselves do not form tumors; they selectively engraft in lung tumors. In 
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addition, tumor burden in SCID mice bearing lung tumors is significantly reduced 
following systemic administration of human IFN-β-expressing UCMS cells. 
Materials and methods 
Tissue culture of human umbilical cord matrix stem cells and MDA 231 
cells  
Human umbilical cord matrix stem (UCMS) cells were harvested following 
deliveries at the time of birth with the mother‘s consent.  The methods to isolate and 
culture human UCMS cells were previously described (Weiss et al., 2006). 
MDA 231, a human breast carcinoma cell line that engrafts in the lung of nude 
mice (Fraker et al., 1984) was maintained in DMEM (Invitrogen, Carlsbad, CA), and 
10% FBS (Mediatech, Herndon, VA) at 37oC in a humidified atmosphere containing 5% 
carbon dioxide.  
Adenoviral vectors and transduction of human UCMS cells 
Since UCMS cells do not express the adenoviral receptor, fiber-modified viruses  
were used to allow efficient transduction (Studeny et al., 2002;Studeny et al., 2004).  
Recombinant adenoviral particles carrying human IFN-β was used (Studeny et al., 
2002;Studeny et al., 2004).  For transduction, the human UCMS cells were plated in T-
75 flasks and infected when the cells reached 80-90% confluency.  The cells were 
washed twice with DMEM without serum and incubated with DMEM containing 
adenovirus at 12,500 viral particles per cell (for adenovirus-IFN-β) for 4 hours at 37oC.  
The cells were cultured in UCMS media (a mixture of 56%  low glucose DMEM 
(Invitrogen), 37% MCBD 201 (Sigma; St. Louis, MO ) and 2% fetal bovine serum (FBS, 
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Mediatech, MTT 35-010-CV) containing 1x insulin-transferrin-selinium-A (ITS, 
Invitrogen), 1x ALBUMax1  (Invitrogen), 1x Pen /Strep (Invitrogen), 1x Amphotericin-B 
(Invitrogen), 10nM dexamethasone (Sigma), 50μM ascorbic acid 2-phosphate (Sigma), 
10ng/ml epidermal growth factor (EGF, R&D systems, Minneapolis, MN), and 10ng/ml 
platelet derived growth factor-BB (PDGF-BB, R&D systems)) for 24 hours and then 
used for transplantation studies.  
IFN-β ELISA 
The amount of IFN-β secreted by UCMS−IFN-β cells into the media was 
quantified by a human interferon beta ELISA kit (PBL biomedical laboratories, New 
Jersey).  UCMS cells were plated at 50,000 cells per well in a 12-well plate.  UCMS 
cells were transduced with adenovirus IFN-β at various amounts (12,500, 6,400 and 
3,200) of adenoviral particles per cell as described above.  One day later, the IFN-β 
level in the medium was determined according to manufacturer’s protocols using 
recombinant IFN-β as a standard.   
In vitro effect of conditioned media from IFN-β expressing UCMS cells on 
MDA 231 cells  
To condition the media, fresh media was added to subconfluent (15,000 
cells/cm2) UCMS cells or UCMS-IFN-β cells and incubated for 24 hrs prior to being 
removed, centrifuged and its bioactivity was examined.  MDA 231 cells were plated in 6-
well plates at a density of 160,000 cells per well with MDA 231 growth media (DMEM 
and 10% FBS).  Twenty four hours later, the media was removed from all the wells and 
the MDA 231 media was replaced with either conditioned media from UCMS cells 
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alone, from UCMS-IFN-β cells or unconditioned UCMS media as a control.  After 3 
days, the cells were trypsinized and counted on a hemocytometer.  The percentage of 
dead cells was estimated using trypan blue exclusion.  Results were also expressed as 
the percentage of cell growth, calculated with the following formula (Studeny et al., 
2004): (Number of MDA 231 cells co-cultured with conditioned media on day 3 – the 
number of MDA 231 cells on day 0)/(number of MDA 231 cells cultured in UCMS media 
on day 3 – number of MDA 231 cells on day 0) X 100.  Three different isolates of UCMS 
cells were used in separate trials and each experiment was done in triplicate.   
Immunohistochemistry staining 
For immunofluorescence staining, tissue sections were washed with phosphate 
buffered saline-0.2% Triton X-100 (PBS TX) and fixed with 70% ethanol and acetone 
(1:1) .  This was followed by washing with three changes of PBS TX.  Tissue sections 
were blocked with 5% normal goat serum in PBS TX for 30 minutes, and followed by 
incubation with primary antibody, anti-human mitochondrial antibody (1:1000, 
Chemicon, Temecula, CA), in PBS TX for overnight.  The tissues were then washed 
three times with PBS TX and incubated with Alexa Fluor 488 conjugated secondary 
antibody (1:1000, Molecular Probes, Carlsbad, CA) for 3 hours.  The tissues were 
incubated for 30 min in Hoechst 33342 (1:100, Sigma) as a counter stain to label the 
nuclei followed by a triple rinse with PBS TX.  The antigens were localized using 
epifluorescence microscopy (Nikon Eclipse) and images were captured using a Roper 
Cool Snap ES camera and Metamorph 7. 
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Fluorescent labeling of human UCMS cells 
For transplanted human UCMS cell identification, the red fluorescent dye SP-DiI 
(Molecular Probes) was dissolved in dimethylsulphoxide (DMSO) at a concentration of 
5mg/ml.  SP-DiI dye was added to culture medium to a final concentration of 10 µg/ ml 
and human UCMS cells were labeled by adding 10 ml of medium with SP-DiI in a T-75 
flask for 24 hours.  Then, cells were washed with PBS, incubated with dye-free medium 
for 4 hours, and used for transplantations.  
Evaluation of tumor formation by human UCMS cells 
For the following three in vivo studies 5 week old female CB-17 SCID mice were 
obtained from Harlan laboratories (Indianapolis, IN).  Mice were held for 1 week after 
arrival to allow them to acclimatize.  They were housed in a barrier room and individual 
cages containing HEPA filters.  Both subcutaneous and systemic transplantation of 
UCMS cells suspended in 200μl PBS were carried out under sterile conditions in a 
laminar flow hood in the barrier room.  Animals were randomly assigned to experimental 
groups.  The first set of mice were transplanted with 2 x 106 human UCMS cells (n=5) 
and 1 x 107 human UCMS cells (n=4) subcutaneously at the flank region.  The 
remaining mice were transplanted with 2 x 106 human UCMS cells (n=5), 3 x 106 human 
UCMS cells (n=2), and 6.5 x 106 human UCMS cells (n=1) intravenously via the lateral 
tail vein.  All the mice were sacrificed 50 days after transplantation by cervical 
dislocation.  Lung, kidney, and liver were collected, snap frozen in liquid nitrogen chilled 
isopentane, and used for immunohistochemistry studies.  All in vivo experiments were 
carried out with proper IACUC and IBC institutional approval. 
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Evaluation of selective engraftment of human UCMS cells 
MDA 231 cells and UCMS cells were transplanted without anesthesia into the 
lateral tail vein using sterile conditions in a laminar flow hood in the barrier room.  
Animals were randomly assigned to experimental groups.  For tumor induction, one set 
of mice were transplanted with 1 X 106 MDA 231 cells (n=8).  This was followed by two 
injections of 1 X 106 fluorescently labeled UCMS cells on day 17 and day 24 after 
injection of MDA 231 cells.  A second set of mice were transplanted with 2 X 106 MDA 
231 cells (n=8).  This was followed by two injections of 1 X 106 fluorescently labeled 
UCMS cells on day 11 and day 18.  All the mice were sacrificed 8 days after the last 
UCMS cell transplant.  Other groups included mice injected with fluorescently labeled 
UCMS cells alone (n=4), and mice injected with sterile PBS only (n=4) as controls.  
Lung weights of control and tumor-bearing animals were measured to estimate tumor 
burden.  Lungs and other organs including spleen, liver, kidney, and bone marrow were 
also harvested as described above for immunohistochemical analysis.   
Evaluation of the effect of IFN-β expressing human UCMS cells on the 
growth of MDA 231 xenografts 
MDA 231 cells and UCMS cells were transplanted without anesthesia as 
described above.  Animals were randomly assigned to experimental groups.  For tumor 
induction, 2 x 106 MDA 231 cells were given via the lateral tail vein (n= 22). 
Fluorescently labeled UCMS−IFN-β cells (0.5 x 106, n=9) or fluorescently labeled UCMS 
cells (0.5 x 106, n=5) were transplanted on day 8 after tumor inoculation.  The UCMS 
cells transplant was repeated twice at 1 week intervals subsequent to the first 
transplant.  Experimental groups also included a negative control group that received 
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neither MDA 231 cells nor UCMS cells (n=6; PBS injections only), and a group with 3 
weekly injections of fluorescently labeled UCMS−IFN-β cells (0.5 x 106, n=6) into non-
tumor bearing mice.  All the mice were sacrificed after 30 days by cervical dislocation.  
Lung weights were measured to estimate tumor burden.  Lung, spleen, liver, kidney, 
and bone marrow were harvested and subjected for histological analysis.   
Statistical analysis  
To evaluate the significance of overall differences in lung weights between all in 
vivo groups, statistical analysis was performed by ANOVA.  A p-value less than 0.05 
were considered as significant.  Following significant ANOVA, post hoc analysis using 
Fisher’s protected least significance difference (PLSD) was used for multiple 
comparisons.  Significance for post hoc testing was set at p < 0.05.  All the lung weight 
data were represented as Mean ± Standard Error on graphs.  Statistical analyses were 
performed by Stat View software, version 5.0.1. (Cary, NC). 
Results 
Secretion of IFN-β by UCMS-IFN-β cells 
The amount of IFN-β in international units (I.U.) secreted by the UCMS−IFN-β 
cells into the media was measured by IFN-β ELISA kit.  IFN-β was secreted by the 
UCMS−IFN-β cells in significant amounts, and there was a trend for more IFN-β release 
into the media when UCMS cells were transduced with a greater number of viral 
particles (VP) per cell (Table 4.1).  IFN-β  was not detected in the conditioned media 
with UCMS cells (data not shown). 
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Table 4.1  IFN-β (international units) secreted by 1x106 human UCMS−IFN-β cells when 
transduced with 12500, 6400 and 3200 IFN-β adeno viralparticles/cell. 
 
In vitro effect of IFN-β secreted by human UCMS-IFN-β cells on MDA 231 
cells 
To investigate whether human UCMS−IFN-β cells have an effect on growth and 
cell viability on MDA 231 cells, conditioned media from human UCMS−IFN-β cells was 
added to MDA 231 cells and its effect was analyzed.  MDA 231 cell proliferation was 
markedly inhibited when cultured with conditioned media from UCMS−IFN-β cells in 
comparison with MDA 231 cells cultured in unconditioned UCMS media (p<0.001,  
Figure 4.1B).  The percentage of dead MDA 231 cells in cultures with conditioned media 
from UCMS−IFN-β cells was significantly higher than in MDA 231 cells cultured in 
unconditioned UCMS media (p<0.001,  Figure 4.1A). 
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Figure 4.1  In vitro effect of human UCMS cells and human UCMS−IFN-β cells 
conditioned media on MDA 231 cells. 
(A): Percentage dead cells and (B): percentage control cell growth of MDA 231 cells 
when treated with UCMS cells and UCMS−IFN-β cells conditioned media.  * Statistically 
significant in comparison with MDA 231 only (p-value < 0.001) 
Human UCMS cells do not form tumors in SCID mice 
All the mice were sacrificed 50 days after UCMS cells injection.  Mice appeared 
healthy and no clinical symptoms were found throughout the experimental period.  No 
gross visible tumors were found around the transplantation sites or in any other regions 
of mice.  Immunohistochemical analysis using serial sections stained by anti-human 
mitochondrial antibodies also failed to detect evidence of tumors in tissues such as 
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kidney, liver, and lungs (Figure 4.2 A, B, and C).  These results suggest that human 
UCMS cells are non-tumorigenic in SCID mice and thus are potentially usable for 
transplantation studies.  
 
Figure 4.2  Absence of tumor formation in SCID mice injected with human UCMS cells. 
A: Kidney section negative for UCMS cells after immunostaining with anti-human 
mitochondrial antibody and Hoechst 33342 nuclear stain (blue) (B): Cross section of 
liver and (C): lung stained with same antibody. (Scale bar =100μm).  (D-F): Selective 
engraftment of fluorescently labeled human UCMS cells in MDA 231 lung tumors 
counterstained with Hoechst 33342 nuclear stain. D and E: Fluorescent micrograph 
showing red labeled human UCMS cells (SP-DiI) counter stained with Hoechst 33342 
nuclear stain (blue) and figure 4.2F is the same section as E but with tumor cells shown 
as green fluorescing cells after detection with antihuman mitochondrial antibody.  (Scale 
bar =100μm). 
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Engraftment of human UCMS cells in MDA 231 xenografts in lungs of SCID 
mice 
Red fluorescent human UCMS cells were found selectively near or within MDA 
231 xenografts in lungs of SCID mice after intravenous transplantation (Figure 4.2 E 
and F).  In contrast, in mice injected with MDA 231 cells alone, no red-fluorescent cells 
were found near or within the tumors (data not shown).  Similarly, in mice injected with 
UCMS cells alone, and mice with PBS alone, no fluorescent cells were found in the 
lungs. These results suggest that UCMS cells are capable of tumor-targeted migration 
and survival in the tumor microenvironment.  Lung weights from non-tumor bearing mice 
that received fluorescently labeled UCMS cells alone were not different than mice 
injected with PBS.  As reported there was significant difference (p<0.05) in lung weights 
in mice that received MDA 231 cells than the mice that did not receive any MDA 231 
cells (Figure 4.3).   
 
Figure 4.3 Effect of human UCMS cells (not expressing IFN-β) on tumor burden. 
 74
Lung weights of mice injected with only MDA 231 cells, MDA 231 and UCMS cells, 
UCMS cells alone (sham MDA 231 transplant), and PBS alone (sham tumor, sham 
transplant) are shown.  * Statistically significant in comparison with mice with MDA 231 
only (p-value < 0.05) 
 
Lungs from tumor bearing mice, not UCMS cell transplanted were not different 
from tumor bearing mice transplanted with fluorescently labeled UCMS cells, indicating 
there was no significant effect of UCMS cells on tumor burden (Figure 4.3).  In the lungs 
of mice injected with MDA 231 cells and fluorescently labeled UCMS cells, a large 
number of fluorescently labeled UCMS cells were found near or within tumors (Figure 
4.2 E, and F) but were not found in kidney, liver or spleen.  
Effect of UCMS-IFN-β cells on MDA 231 lung tumor burden in SCID mice 
To test the hypothesis that UCMS−IFN-β cells would reduce the tumor burden in 
lungs of mice injected with MDA 231 cells, lung weights were used to estimate of tumor 
burden and lungs from various groups were photographed (Figure 4.4).   
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Figure 4.4  Representative lungs of experimental groups. 
Group A. MDA 231+UCMS-IFN-β, Group B. MDA 231 alone, Group C. UCMS-IFN-β 
cells, no tumor cells, and Group D. PBS alone  
 
Tumor burden was significantly reduced in MDA 231 inoculated mice 
transplanted with UCMS−IFN-β cells compared with mice inoculated with MDA 231 cells 
alone (p<0.01).  In fact, the burden was reduced by about 50% (Figure 4.5).  Lungs 
weights from mice that received only UCMS−IFN-β cells but not MDA tumor cells were 
not different than sham-treated mice (non significant (NS), p>0.05).  Mice injected with 
UCMS−IFN-β cells alone did not show any adverse effects.  Histological analysis 
revealed that engraftment of UCMS cells was detected in close proximity or within lung 
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tumor tissues of tumor bearing mice that either received fluorescently labeled 
UCMS−IFN-β cells or fluorescently labeled un-engineered UCMS cells (Figure 4.2 D).  
No fluorescently labeled UCMS cells were found in other tissues such as liver, spleen, 
and kidney.  
 
Figure 4.5  Comparative Lung weights. 
Lung weights of mice which were injected with both MDA 231 and UCMS−IFN-β cells 
compared with mice injected with MDA 231 alone, UCMS−IFN-β cells alone and sham 
transplanted mice with no tumors.  * Statistically significant in comparison with mice with 
MDA 231 only (p-value < 0.01).  
Discussion 
Here, we provide evidence that unique primitive human stem cells can be 
harvested rapidly in large numbers from umbilical cord Wharton's jelly do not 
themselves form tumors, and thus they are safe, practical delivery vehicles for specific 
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genes.  For the first time, we show that UCMS cells selectively engraft in tumors, can be 
engineered to secrete a therapeutic protein, IFN-β, and significantly reduce lung 
metastasized breast carcinoma tumor burden in an animal model. 
When undifferentiated embryonic stem cells (ESCs) are transplanted  they 
sometimes form tumors (Thomson and Marshall, 1998;Wakitani et al., 2003;Arnhold et 
al., 2004;Ishikawa et al., 2004); therefore, we tested whether UCMS cells might have 
that tendency.  UCMS cells are karyotypically stable over passages and do not lose 
anchorage dependency, contact inhibition or serum dependence (Weiss et al., 
2006;Karahuseyinoglu et al., 2007), which are characteristics of cancer cells.  Our in 
vivo findings support the in vitro published data, since they do not become tumorigenic 
and hence are safe from that standpoint.  This is an important consideration, since 
these cells express some of the same primitive genes expressed by ESCs (Carlin et al., 
2006). 
IFN-β induces apoptosis in cancer cells mainly by disrupting mitochondria and 
activation of the caspase cascade (Juang et al., 2004).  It also is a potent inhibitor  of 
proliferation for many cancer cells in vitro (Wong et al., 1989;Johns et al., 1992).  
However, it cannot be used effectively as cancer therapy because the maximum 
tolerated dose is not high enough to attain these effects when it is given systemically 
(Salmon et al., 1996;Einhorn and Grander, 1996;Buchwalder et al., 2000) and it has a 
short half-life.  Although it has been shown that serum levels of interferon delivered by 
engineered stem cells are insignificant in contrast to interferon given systemically 
(Studeny et al., 2004),  the local production of IFN-β appears to be the key for tumor 
growth attenuation.  The stem cell-based gene therapy can also avoid potential 
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systemic adverse effects of IFN-β.  Since we found no long term engraftment of UCMS 
cells in the evaluation of tumor formation by stem cells (Figure 4.2 A-C), it is 
conceivable that the engrafted stem cells will not remain for a long period of time after 
attenuation of the tumor.  In more recent work, we have engineered the UCMS cells 
with a thymidine kinase suicide gene as an additional safety feature (unpublished data).  
Taken together, our UCMS cell-based tumor-targeted IFN-β gene delivery appears to be 
a safe, effective, and practical cancer gene therapy. 
The adenoviral system used to engineer the UCMS cells was fiber-modified to 
facilitate viral entry into the cells, since some cells may not express the coxsackie virus 
and adenovirus receptor (CAR) receptor necessary for cell entry (Dmitriev et al., 1998).  
Our in vitro testing of this fiber-modified vector established that it was considerably more 
efficient than transduction with unmodified adenoviral vectors (data not shown); this is 
consistent with other reports (Dmitriev et al., 1998;Mizuguchi et al., 2001;Koizumi et al., 
2001). 
The finding that UCMS cells administered via the tail vein exhibited a selective 
engraftment to the MDA 231 lung tumors of SCID mice suggests that they may respond 
to chemotactic signals emanating from the tumor cells.  Others have reported that 
tumors secrete factors that recruit stromal, vascular, bone marrow and other stem cells 
to the tumor; theoretically the recruited cells provide a scaffolding and source of 
nutrients (Tlsty and Hein, 2001;van Kempen et al., 2003).  Several chemokines are 
known to be secreted by tumors that may mediate the observed tropism, including 
VEGF, TGF family members, FGF family members, PDGF family members, MCP-1, 
EGF and IL-8 (Nakamura et al., 2004).  Cells related to UCMS cells, bone marrow 
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MSCs, have been shown to exhibit a tropism for damaged or rapidly growing tissues as 
well as tumors (Azizi et al., 1998;Kopen et al., 1999;Studeny et al., 2002;Studeny et al., 
2004;Nakamizo et al., 2005).  The human UCMS cells have been characterized by gene 
array and cytokine array previously (Weiss et al., 2006), and express possible 
chemokine receptors such as SDFR1, TGFBR3, FGFR2 (Weiss et al., 2006). 
In summary, human UCMS cells are unique stem cells derived from the 
Wharton’s jelly of the umbilical cord and do not form tumors in SCID mice.  Second, 
they selectively engraft in MDA 231 lung tumors.  Third, UCMS cells that were 
engineered to express IFN-β can deliver sufficient IFN-β to kill MDA 231 cells in vitro.  
Finally, UCMS−IFN-β cell transplantation into lung tumor-bearing SCID mice produces a 
significant reduction of the tumor burden.  Thus, these results suggest that UCMS cells 
may be a platform for targeted delivery of therapeutic proteins to human breast cancer 
and other types of cancer. 
 
 
Acknowledgments: 
 
The authors would like to thank Marla Pyle for technical assistance and 
manuscript proof reading, Matt Martinez and Erin Miller for laboratory assistance in 
tissue sectioning and in vitro studies.  This work represents contributions from the NIH 
NS 34160, Terry C. Johnson Cancer Center, Kansas State Legislature, and the Kansas 
Agricultural Experiment Station. 
 
 
 
 80
 
References Cited 
 
 1.  Aboody, K. S. et al., 2000, Neural stem cells display extensive tropism for 
pathology in adult brain: evidence from intracranial gliomas: 
Proc.Natl.Acad.Sci.U.S.A, v. 97, no. 23, p. 12846-12851. 
 2.  Arnhold, S., H. Klein, I. Semkova, K. Addicks, and U. Schraermeyer, 2004, 
Neurally selected embryonic stem cells induce tumor formation after long-term 
survival following engraftment into the subretinal space: Invest 
Ophthalmol.Vis.Sci., v. 45, no. 12, p. 4251-4255. 
 3.  Azizi, S. A., D. Stokes, B. J. Augelli, C. DiGirolamo, and D. J. Prockop, 1998, 
Engraftment and migration of human bone marrow stromal cells implanted in the 
brains of albino rats--similarities to astrocyte grafts: Proc.Natl.Acad.Sci.U.S.A, v. 
95, no. 7, p. 3908-3913. 
 4.  Brown, A. B., W. Yang, N. O. Schmidt, R. Carroll, K. K. Leishear, N. G. Rainov, 
P. M. Black, X. O. Breakefield, and K. S. Aboody, 2003, Intravascular delivery of 
neural stem cell lines to target intracranial and extracranial tumors of neural and 
non-neural origin: Hum.Gene Ther., v. 14, no. 18, p. 1777-1785. 
 5.  Buchwalder, P. A., T. Buclin, I. Trinchard, A. Munafo, and J. Biollaz, 2000, 
Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers: 
J.Interferon Cytokine Res., v. 20, no. 10, p. 857-866. 
 6.  Carlin, R., D. Davis, M. Weiss, B. Schultz, and D. Troyer, 2006, Expression of 
early transcription factors Oct4, Sox2 and Nanog by porcine umbilical cord (PUC) 
matrix cells: Reprod.Biol.Endocrinol., v. 4, no. 1, p. 8. 
 7.  Chawla-Sarkar, M., D. W. Leaman, and E. C. Borden, 2001, Preferential 
induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: 
 81
correlation with TRAIL/Apo2L induction in melanoma cell lines: Clin.Cancer Res., 
v. 7, no. 6, p. 1821-1831. 
 8.  Conconi, M. T., P. Burra, L. R. Di, C. Calore, M. Turetta, S. Bellini, P. Bo, G. G. 
Nussdorfer, and P. P. Parnigotto, 2006, CD105(+) cells from Wharton's jelly 
show in vitro and in vivo myogenic differentiative potential: Int.J.Mol.Med., v. 18, 
no. 6, p. 1089-1096. 
 9.  Dmitriev, I., V. Krasnykh, C. R. Miller, M. Wang, E. Kashentseva, G. Mikheeva, 
N. Belousova, and D. T. Curiel, 1998, An adenovirus vector with genetically 
modified fibers demonstrates expanded tropism via utilization of a coxsackievirus 
and adenovirus receptor-independent cell entry mechanism: J.Virol., v. 72, no. 
12, p. 9706-9713. 
 10.  Einhorn, S., and D. Grander, 1996, Why do so many cancer patients fail to 
respond to interferon therapy?: J.Interferon Cytokine Res., v. 16, no. 4, p. 275-
281. 
 11.  Fraker, L. D., S. A. Halter, and J. T. Forbes, 1984, Growth inhibition by retinol of 
a human breast carcinoma cell line in vitro and in athymic mice: Cancer Res., v. 
44, no. 12 Pt 1, p. 5757-5763. 
 12.  Fu, Y. S., Y. C. Cheng, M. Y. Lin, H. Cheng, P. M. Chu, S. C. Chou, Y. H. Shih, 
M. H. Ko, and M. S. Sung, 2006, Conversion of human umbilical cord 
mesenchymal stem cells in Wharton's jelly to dopaminergic neurons in vitro: 
potential therapeutic application for Parkinsonism: Stem Cells, v. 24, no. 1, p. 
115-124. 
 13.  Hoerstrup, S. P., A. Kadner, C. Breymann, C. F. Maurus, C. I. Guenter, R. 
Sodian, J. F. Visjager, G. Zund, and M. I. Turina, 2002, Living, autologous 
pulmonary artery conduits tissue engineered from human umbilical cord cells: 
Ann.Thorac.Surg., v. 74, no. 1, p. 46-52. 
 82
 14.  Ishikawa, T. et al., 2004, Characterization of in vitro gutlike organ formed from 
mouse embryonic stem cells: Am.J.Physiol Cell Physiol, v. 286, no. 6, p. C1344-
C1352. 
 15.  Johns, T. G., I. R. Mackay, K. A. Callister, P. J. Hertzog, R. J. Devenish, and A. 
W. Linnane, 1992, Antiproliferative potencies of interferons on melanoma cell 
lines and xenografts: higher efficacy of interferon beta: J.Natl.Cancer Inst., v. 84, 
no. 15, p. 1185-1190. 
 16.  Juang, S. H., S. J. Wei, Y. M. Hung, C. Y. Hsu, D. M. Yang, K. J. Liu, W. S. 
Chen, and W. K. Yang, 2004, IFN-beta induces caspase-mediated apoptosis by 
disrupting mitochondria in human advanced stage colon cancer cell lines: 
J.Interferon Cytokine Res., v. 24, no. 4, p. 231-243. 
 17.  Karahuseyinoglu, S., O. Cinar, E. Kilic, F. Kara, G. G. Akay, D. O. Demiralp, A. 
Tukun, D. Uckan, and A. Can, 2007, Biology of stem cells in human umbilical 
cord stroma: in situ and in vitro surveys: Stem Cells, v. 25, no. 2, p. 319-331. 
 18.  Koizumi, N., H. Mizuguchi, T. Hosono, A. Ishii-Watabe, E. Uchida, N. Utoguchi, 
Y. Watanabe, and T. Hayakawa, 2001, Efficient gene transfer by fiber-mutant 
adenoviral vectors containing RGD peptide: Biochim.Biophys.Acta, v. 1568, no. 
1, p. 13-20. 
 19.  Kopen, G. C., D. J. Prockop, and D. G. Phinney, 1999, Marrow stromal cells 
migrate throughout forebrain and cerebellum, and they differentiate into 
astrocytes after injection into neonatal mouse brains: Proc.Natl.Acad.Sci.U.S.A, 
v. 96, no. 19, p. 10711-10716. 
 20.  Lokshin, A., J. E. Mayotte, and M. L. Levitt, 1995, Mechanism of interferon beta-
induced squamous differentiation and programmed cell death in human non-
small-cell lung cancer cell lines: J.Natl.Cancer Inst., v. 87, no. 3, p. 206-212. 
 83
 21.  Medicetty, S., A. R. Bledsoe, C. B. Fahrenholtz, D. Troyer, and M. L. Weiss, 
2004, Transplantation of pig stem cells into rat brain: proliferation during the first 
8 weeks: Exp.Neurol., v. 190, no. 1, p. 32-41. 
 22.  Mitchell, K. E. et al., 2003, Matrix cells from Wharton's jelly form neurons and 
glia: Stem Cells, v. 21, no. 1, p. 50-60. 
 23.  Mizuguchi, H., N. Koizumi, T. Hosono, N. Utoguchi, Y. Watanabe, M. A. Kay, and 
T. Hayakawa, 2001, A simplified system for constructing recombinant adenoviral 
vectors containing heterologous peptides in the HI loop of their fiber knob: Gene 
Ther., v. 8, no. 9, p. 730-735. 
 24.  Nakamizo, A. et al., 2005, Human bone marrow-derived mesenchymal stem cells 
in the treatment of gliomas: Cancer Res., v. 65, no. 8, p. 3307-3318. 
 25.  Nakamura, K. et al., 2004, Antitumor effect of genetically engineered 
mesenchymal stem cells in a rat glioma model: Gene Ther., v. 11, no. 14, p. 
1155-1164. 
 26.  Salmon, P., J. Y. Le Cotonnec, A. Galazka, A. bdul-Ahad, and A. Darragh, 1996, 
Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta 
in healthy male volunteers: J.Interferon Cytokine Res., v. 16, no. 10, p. 759-764. 
 27.  Studeny, M., F. C. Marini, R. E. Champlin, C. Zompetta, I. J. Fidler, and M. 
Andreeff, 2002, Bone marrow-derived mesenchymal stem cells as vehicles for 
interferon-beta delivery into tumors: Cancer Res., v. 62, no. 13, p. 3603-3608. 
 28.  Studeny, M., F. C. Marini, J. L. Dembinski, C. Zompetta, M. Cabreira-Hansen, B. 
N. Bekele, R. E. Champlin, and M. Andreeff, 2004, Mesenchymal stem cells: 
potential precursors for tumor stroma and targeted-delivery vehicles for 
anticancer agents: J.Natl.Cancer Inst., v. 96, no. 21, p. 1593-1603. 
 29.  Thomson, J. A., and V. S. Marshall, 1998, Primate embryonic stem cells: 
Curr.Top.Dev.Biol., v. 38, p. 133-165. 
 84
 30.  Tlsty, T. D., and P. W. Hein, 2001, Know thy neighbor: stromal cells can 
contribute oncogenic signals: Curr.Opin.Genet.Dev., v. 11, no. 1, p. 54-59. 
 31.  van Kempen, L. C., D. J. Ruiter, G. N. van Muijen, and L. M. Coussens, 2003, 
The tumor microenvironment: a critical determinant of neoplastic evolution: 
Eur.J.Cell Biol., v. 82, no. 11, p. 539-548. 
 32.  Wakitani, S., K. Takaoka, T. Hattori, N. Miyazawa, T. Iwanaga, S. Takeda, T. K. 
Watanabe, and A. Tanigami, 2003, Embryonic stem cells injected into the mouse 
knee joint form teratomas and subsequently destroy the joint: 
Rheumatology.(Oxford), v. 42, no. 1, p. 162-165. 
 33.  Wang, H. S., S. C. Hung, S. T. Peng, C. C. Huang, H. M. Wei, Y. J. Guo, Y. S. 
Fu, M. C. Lai, and C. C. Chen, 2004, Mesenchymal stem cells in the Wharton's 
jelly of the human umbilical cord: Stem Cells, v. 22, no. 7, p. 1330-1337. 
 34.  Weiss, M. L. et al., 2006, Human umbilical cord matrix stem cells: preliminary 
characterization and effect of transplantation in a rodent model of Parkinson's 
disease: Stem Cells, v. 24, no. 3, p. 781-792. 
 35.  Weiss, M. L., K. E. Mitchell, J. E. Hix, S. Medicetty, S. Z. El-Zarkouny, D. 
Grieger, and D. L. Troyer, 2003, Transplantation of porcine umbilical cord matrix 
cells into the rat brain: Exp.Neurol., v. 182, no. 2, p. 288-299. 
 36.  Wong, V. L., D. J. Rieman, L. Aronson, B. J. Dalton, R. Greig, and M. A. Anzano, 
1989, Growth-inhibitory activity of interferon-beta against human colorectal 
carcinoma cell lines: Int.J.Cancer, v. 43, no. 3, p. 526-530. 
 
 
 
 
 
 
 
 85
CHAPTER 5 - Combination treatment of human umbilical 
cord matrix stem cell-based interferon-beta gene therapy and 
5-fluorouracil significantly reduces growth of metastatic 
human breast cancer in SCID mouse lungs 
 
Raja Shekar Rachakatla1, Marla M Pyle1, Rie Ayuzawa1, Sarah M Edwards1, Frank C 
Marini2, Mark L Weiss1, Masaaki Tamura1, Deryl Troyer *,1 
1Dept of Anatomy & Physiology, Kansas State University, Manhattan, KS, USA 
2Dept of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer 
Center, Houston, TX, USA 
 
 
* Corresponding author 
 
E-mail: Deryl Troyer, troyer@vet.k-state.edu 
 
 
 
 
 
Key Words. Interferon-beta; lung tumors; UCMS cells; MDA-231 breast carcinoma 
cells; 5-fluorouracil. 
 86
Abstract 
Umbilical cord matrix stem (UCMS) cells that were engineered to express 
interferon-beta (IFN-β) were transplanted weekly for three weeks into MDA 231 breast 
cancer xenografts bearing SCID mice in combination with 5-fluorouracil (5-FU). The 
UCMS cells were found within lung tumors but not in other tissues.  Although both 
treatments significantly reduced MDA 231 tumor area in the SCID mouse lungs, the 
combined treatment resulted in a greater reduction in tumor area than by either 
treatment used alone. These results indicate that a combination treatment of UCMS-
IFN-β cells and 5-FU is a potentially effective therapeutic procedure for breast cancer. 
 
1. Introduction 
Tumors behave much like wounds that do not heal (Dvorak, 1986).  Bone 
marrow mesenchymal stem cells (MSCs) (Natsu et al., 2004;Rojas et al., 2005) and 
neural stem cells (Aboody et al., 2000;Brown et al., 2003) migrate toward wounds and 
other areas of pathology and have been shown to be effective gene-delivery vehicles for 
targeted cancer therapy (Aboody et al., 2000;Studeny et al., 2002;Brown et al., 
2003;Studeny et al., 2004;Nakamura et al., 2004).  However, bone marrow cells require 
painfully invasive procedures to harvest and require considerable time for expansion.  
On the other hand, umbilical cord matrix stem (UCMS) cells, isolated from Wharton’s 
jelly of the umbilical cord (Mitchell et al., 2003), are unique in that they are prenatal cells 
isolated postnatally, and in contrast to many postnatal stem cells, can be harvested 
non-invasively in large numbers.  Gene array and RT PCR data indicate that UCMS 
cells express genes expressed by undifferentiated embryonic stem cells (ESCs), 
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including those of the LIF receptor pathway, ESG1, SOX2, Oct4, Nanog and TERT 
(Weiss et al., 2006;Carlin et al., 2006).  Human UCMS cells express markers of three 
germ layer derivatives: mesoderm: ACTG2, ACTA2, BMP1, PDGFB; ectoderm: 
cytokeratin, SHH; and endoderm: insulin.  Given their primitive nature, it is worrisome 
that UCMS cells might tend to form teratomas, as is the case with ESCs (Thomson and 
Marshall, 1998;Wakitani et al., 2003;Arnhold et al., 2004;Ishikawa et al., 2004).  
However, they do not become tumorgenic after multiple passages (Karahuseyinoglu et 
al., 2007) or after transplantation of large numbers into SCID mice (Rachakatla et al., 
2007).  
The cytokine interferon-beta (IFN-β) is known to have multiple effects such as 
immunostimulation, inhibition of tumor growth and angiogenesis (Sidky and Borden, 
1987;Singh et al., 1995;Qin et al., 1997;Stark et al., 1998;Qin et al., 1998).  In an earlier 
experiment, we found that UCMS cells engineered to secrete IFN-β trafficked to and 
reduced the tumor burden of lung tumors in SCID mice (Rachakatla et al., 2007).  Here, 
we investigated whether further reduction of tumor burden could be effected by 
increasing the expression of IFN-β by the UCMS cells and by using this targeted 
delivery in combination with a low dose of 5-Fluorouracil (5-FU).  5-FU is a widely used 
chemotherapeutic agent that often has significant hematological and digestive toxic side 
effects (Douillard et al., 2000); however, those side effects are substantially reduced at 
a lower dose.  Choi et al have shown that combination of adenoviral mediated IFN-β 
gene therapy and 5-FU have reduced tumors and improved the survival rates of liver 
metastatic tumor bearing mice models (Choi et al., 2004).  Accordingly, our hypothesis 
was that stem cell mediated targeted delivery of IFN-β would allow the use of reduced 
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dosages of 5-FU.  Here, we report for the first time that stem cell-mediated gene 
delivery of IFN-β, in combination with systemic treatment of low doses of 5-FU, results 
in significant additive effects on tumor attenuation in a rodent model of metastatic breast 
carcinoma. 
2. Materials and Methods 
2.1. Tissue culture of human umbilical cord matrix stem cells and MDA 231 
cells 
Human umbilical cord matrix stem (UCMS) cells were harvested from term 
deliveries at the time of birth with the mother‘s consent.  The methods to isolate and 
culture human UCMS cells were previously described (Weiss et al., 2006).  Human 
UCMS cells were maintained in defined medium (DM), a mixture of 56% low glucose 
DMEM (Invitrogen), 37% MCBD 201 (Sigma; St. Louis, MO) and 2% fetal bovine serum 
(FBS, Atlanta Biologicals Inc, Georgia) containing 1x insulin-transferrin-selenium-X 
(ITS-X, Invitrogen, CA), 1x ALBUMax1 (Invitrogen, CA), 1x Pen /Strep (Invitrogen, CA), 
10nM dexamethasone (Sigma, MO), 100μM ascorbic acid 2-phosphate (Sigma, MO), 
10ng/ml epidermal growth factor (EGF, R&D systems, Minneapolis), and 10ng/ml 
platelet derived growth factor-BB (PDGF-BB, R&D systems, MN), at 37oC in a 
humidified atmosphere containing 5% carbon dioxide. 
MDA 231 human breast carcinoma cells that metastasize to the lung in nude 
mice were obtained from M.D. Anderson Cancer Center (Houston, TX) (Studeny et al., 
2002).  They were maintained in DMEM (Invitrogen, CA), 1x Pen/Strep (Invitrogen, CA), 
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and 10% FBS (Atlanta Biologicals Inc, GA), at 37oC in a humidified atmosphere 
containing 5% carbon dioxide. 
2.2. Transduction of human UCMS cells with recombinant IFN-β adenovirus 
vector and quantification of IFN-β 
Since UCMS cells (like bone marrow MSC) do not express the adenoviral 
receptor, they were engineered using fiber-modified IFN-β recombinant adenovirus 
(Studeny et al., 2002), developed by one of us (F. M.).  For transduction, the human 
UCMS cells were washed twice with DMEM without serum and cells were incubated 
with DMEM containing adenovirus at 100,000 plaque forming units (PFU) per cell for 4 
hours at 37oC.  Defined medium (DM) containing 5% FBS was added after incubation 
and the cells were used for in vivo transplantation the next day.  The amount of IFN-β 
secreted by UCMS−IFN-β cells into the medium was quantified by a human interferon-
beta ELISA kit (PBL Biomedical Laboratories, New Jersey).  For quantification of IFN-β, 
UCMS cells were plated at 50,000 cells per well in a 12-well plate.  UCMS cells were 
transduced with adenovirus expressing IFN-β at concentrations of 10,000, 25,000, 
50,000, and 100,000 PFU per cell.  The UCMS−IFN-β cells were cultured for 96 hours 
and media was collected at 24, 48 and 96 hours and stored at -800C until use.  After 
collecting media at 3 different time points, ELISA assay was carried out according to 
manufacturer’s protocols. 
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2.3. In vitro apoptotic effect of conditioned medium from UCMS-IFN-β cells 
on MDA 231 cells 
To condition the media, fresh DM containing 5% FBS was added to sub-
confluent (20,000 cells/cm2) UCMS cells and UCMS-IFN-β cells and cultured for 48 
hours (first 48 hours, 0-48 hours from transduction).  The conditioned medium (CM) was 
removed and the cells refed and cultured for an additional 48 hours (second 48 hours, 
48-96 hours from transduction).  The CM was removed and stored at -80°C until use.  
The MDA 231 cells (0.25 x 106 cells/well) were cultured in 6-well plates with DM 
containing 5% FBS.  Cells were then incubated until approximately 90% confluency was 
reached (approximately 48 hours), at which time the medium was changed to various 
types of DM-diluted conditioned media (CM, 1:1=DM:CM).  The assay was carried out 
with quadruplicate determinations and was repeated at least twice.  Following the 
medium change to the conditioned media, the cells were incubated for a period of 24 
hours and their apoptotic index was analyzed.  When cells had been treated as 
described above, they were prepared for Annexin V-FITC FACS analysis, according to 
manufacturer’s protocol.  The cells were first washed with PBS, trypsinized and 
resuspended in DM containing 5% FBS.  Approximately 2 x 105 MDA 231 cells from 
various treatments were subjected to evaluation of apoptosis index by the Annexin V-
FITC Apoptosis Detection Kit (Bio Vision Inc. Mountain View, CA).  The FACS analysis 
was carried out by FACSVantage SE flow cytometer (BD Biosciences, San Jose, CA). 
Additionally, we examined caspase activations after the combination treatment.  
MDA 231 cells were plated in 6-well plates at a density of 200,000 cells per well with 
DM containing 5% FBS.  Twenty four hours later, the medium was removed from all the 
 91
wells and was replaced with either 5-FU (10μg, 100μg, 250μg/ml of DM), or DM-diluted 
CM from UCMS-IFN-β cells (second 48 hours conditioned medium) or a combination of 
both.  The cells were allowed to incubate for 36 and 48 hours.  Later, cells were lysed 
with lysis buffer (1% Triton,0.1%SDS, 0.25M sucrose, 1mM EDTA, 30mM Tris-HCl 
pH8.0 and 7x complete mini EDTA-free stock solution (Roche Diagnostics, IN) at ratio 
of 1:7) followed by sonication and boiling.  After cells were lysed, 1/4 volume of 5x SDS-
PAGE sample buffer was added to the cell lysis solution.  Whole cell protein was 
separated with 12%SDS-PAGE and transferred to nitrocellusose membrane (GE 
Healthcare, NJ). The membrane was probed with a specific primary antibody 
(procaspase-3, cleaved caspase-3 (Cell Signaling Technology, MA)) and GAPDH 
(Santa Cruz Biotechnology, CA) at dilution of 1: 1000 to 1: 4000, followed by washing 
and probing with anti-rabbit HRP-antibody (GE Healthcare, NJ) at dilution of 1: 2000. 
The specific protein band was visualized by a Kodak image station using a super signal 
kit (Price Biotechnology, IL). 
2.4. In vitro additive effect of 5-FU and UCMS-IFN-β cell conditioned 
medium on cell proliferation and viability of MDA 231 cells 
MDA 231 cells were plated in 6-well plates at a density of 200,000 cells per well 
with DM containing 5% FBS.  Twenty four hours later, the medium was removed from 
all the wells and was replaced with either 5-FU (10μg, 100μg, 250μg/ml of DM), or DM-
diluted CM from UCMS-IFN-β cells (second 48 hours conditioned medium) or a 
combination of both.  After 24 hours, the cells were trypsinized; cell proliferation and 
viability were quantified by MTT assay (Roche Applied Science, IN) as per 
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manufacturer’s protocol.  Three different isolates of UCMS cells were used in separate 
trials and each experiment was done in triplicate. 
2.5. Identification of human UCMS cells and MDA 231 cells in mouse 
tissues 
For transplanted stem cell identification, the fluorescent dye SP-DiI (Molecular 
Probes, CA) was dissolved in dimethylsulfoxide (DMSO) at a concentration of 5mg/ml.  
SP-DiI dye was added to culture medium to a final concentration of 10µg/ml and human 
UCMS cells were labeled by adding 10 ml of medium with SP-DiI in a T-75 flask for 24 
hours.  Then, cells were washed with PBS, incubated with dye-free medium for 4 hours, 
and used for experiments.  Immunohistochemistry was used to identify the MDA 231 
cells in mouse lung.  Tissue sections were washed with phosphate buffered saline-0.2% 
Triton X-100 (PBS TX) and fixed with 70% ethanol and acetone (1:1).  This was 
followed by washing with three changes of PBS TX.  To more clearly delineate tumor 
cells, tissue sections were blocked with 5% normal goat serum in PBS TX for 30 
minutes, followed by incubation with anti-human mitochondrial antibody (1:100, 
Chemicon, CA), in PBS TX overnight.  The tissues were then washed three times with 
PBS TX and incubated with Alexa Fluor 488 conjugated secondary antibody (1:1000, 
Molecular Probes, CA) for 3 hours.  The tissues were incubated for 30 min. in Hoechst 
33342 (10μg/ml, Sigma, MO) nuclear counterstain, followed by a triple rinse with PBS 
TX.  The antigens were localized using epifluorescence microscopy (Nikon Eclipse, 
Boyce Scientific Inc. MO) and images were captured using a Roper Cool Snap ES 
camera and Metamorph 7. 
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2.6. Evaluation of the in vivo effect of 5-FU and human UCMS-IFN-β cells on 
MDA 231 tumors 
Female CB-17 SCID mice (5 weeks old) were obtained from Harlan Laboratories 
(Indiana).  Mice were held for 1 week after arrival to allow them to acclimate.  MDA 231 
cells (2 X 106) were transplanted into the lateral tail vein using sterile conditions.  Eight 
days after tumor transplant, mice were randomized into five groups: 1) sham UCMS cell 
transplant; 2) UCMS−IFN-β cell (0.5 X 106) transplant; 3) un-engineered UCMS cell (0.5 
X 106) transplant; 4) UCMS−IFN-β cell transplant and 5-FU (40mg/kg), given via 
intraperitoneal (IP) injection 3 days after each UCMS−IFN-β cell transplant); and 5) 5-
FU given alone on days corresponding to group 4 injections.  An additional group that 
received saline sham tumor cell and stem cell transplants served as untreated controls.  
All the mice were sacrificed 30 days after tumor inoculation by CO2 inhalation and 
cervical dislocation.  Lung weights of control and tumor-bearing animals were measured 
to estimate tumor burden (ANOVA followed by post-hoc planned comparison).  Lungs 
were snap-frozen in isopentane in liquid nitrogen for histological and/or 
immunohistochemical (IHC) analysis.  Other organs including spleen, liver, kidney, and 
bone marrow were also harvested.  Tissues were sectioned on a cryostat at 7-8 µm and 
used for IHC studies.  Random tissue sections from each group of SCID mice were 
taken to measure the tumor area in the lungs.  Immunohistochemistry, performed as 
described above using anti-human mitochondrial antibody, served to outline the MDA 
231 tumors with green fluorescence.  The area (in square micrometers) occupied by the 
tumor was calculated from 10-15 200x fields for each group of mice using the 
MetaMorph 7 image analysis system as described elsewhere (Koka et al., 
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2006;Richards et al., 2007).  Several investigators have calculated random areas in a 
tissue section and have correlated it to overall tissue section using the MetaMorph 7 
image analysis system (Koka et al., 2006;Richards et al., 2007). 
2.7. Statistical analysis 
The means of the experimental groups were evaluated to confirm that they met 
the normality assumption.  For in vitro experiments, statistical analysis was performed 
with the student’s t-test.  To evaluate the significance of overall differences in tumor 
areas between all in vivo groups, statistical analysis was performed by ANOVA.  A p-
value less than 0.05 was considered as significant.  Following significant ANOVA, post 
hoc analysis using Fisher’s protected least significance difference (PLSD) was used for 
multiple comparisons.  Significance for post hoc testing was set at p < 0.05.  All the 
tumor area data were represented as mean ± standard error on graphs.  Statistical 
analyses were performed by Stat View software, version 5.0.1. (Cary, NC). 
3. Results 
3.1. Quantification of IFN-β secreted by UCMS-IFN-β cells 
The amount of IFN-β secreted by the UCMS−IFN-β cells into the medium was 
measured by ELISA kit (Table 1).  IFN-β was secreted in significant amounts and there 
was a trend for more IFN-β release into the medium when UCMS cells were transduced 
with a greater number of plaque forming units.  The time-dependent increase of IFN-β 
secretion was also observed when UCMS−IFN-β cells were incubated for 24, 48, and 
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96 hours (second 48 hour incubation after the medium change) after the IFN-β 
transfection (Table 5.1).  
 
Table 5.1  The levels of IFN-β secreted by 1x106 human IFN-β transfected UCMS cells 
were dose- and time-dependently increased.  
Designated amounts (PFU/cell) of adenovirus vector containing IFN-β DNA were 
incubated with UCMS cells for 24, 48 and 96 hours. The level of IFN-β was quantified 
by ELISA as described in the methods section. Twenty four and 48 hour samples were 
obtained from the conditioned medium incubated with transfected cells for 24 and 48 
hours after the transfection, respectively. The second 48 hour sample was collected 
from 48-96 hours after transfection. 
3.2. Effect of UCMS−IFN-β cell conditioned medium (CM) on apoptosis of 
MDA 231 cells 
To investigate the effect of UCMS−IFN-β cell CM upon apoptosis of MDA 231 
cells, the MDA 231 cells were cultured with CM from UCMS cells and UCMS−IFN-β 
cells for several time intervals.  The percentage of MDA 231 cells in late apoptosis 
significantly increased in cells cultured with both first 48 hours (data not shown) and 
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second 48 hours UCMS−IFN-β cell CM (Figure 5.1) in comparison with MDA 231 cells 
cultured with unconditioned DM or UCMS cell CM (i.e., since the 0-48 hr CM from 
UCMS−IFN-β showed a similar effect on the tumor cells as the 48-96 hr interval, only 
the latter is shown). The percentage of cells in early apoptosis in the MDA 231 cells 
cultured with UCMS−IFN-β cell CM was significantly higher than unconditioned DM 
group (Figure 5.1).   
 
Figure 5.1  In vitro apoptotic effect of UCMS-IFN-β cell conditioned medium on MDA 
231 cells.   
Percentage of cells in early and late apoptosis when treated with second 48 hours CM 
(48-96 hours from the transduction).  * Statistically significant (t-value less than 0.05). 
 
The conditioned medium obtained from non-interferon-expressing UCMS cells 
showed some effect on cancer cell apoptosis in this study; however, the IFN-β 
transfected UCMS-derived conditioned medium always exhibited a stronger apoptotic 
effect than the conditioned medium obtained from the UCMS cells alone in the parallel 
study.  
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Western blot results showed that procaspase-3 is decreased and activated 
caspase-3 is increased in combination therapy of 5-FU and UCMS-IFN-β cells (Figure 
5.2).These results clearly indicate that the combination treatment of UCMS−IFN-β cells 
and 5-FU decreased cell viability and increased the apoptosis more effectively than 
individual treatment. 
 
Figure 5.2   Western blot analysis of caspase 3 activation in MDA 231 cells treated with 
5-FU and the conditioned medium with UCMS-IFN-β cells. 
In this experiment, a combination treatment with 5-FU and the conditioned medium 
significantly stimulated an activation of caspase 3.  Note that the treatment with low 
concentration (10 and 100 µg) of 5-FU and conditioned medium significantly increased 
band intensities of the cleaved caspase 3 in a time-dependent manner. 
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3.3. Effect of 5-FU and UCMS−IFN-β cell conditioned medium on MDA 231 
cell proliferation and viability 
 To investigate the effect of 5-FU and UCMS−IFN-β cell CM on proliferation 
and viability of MDA 231 cells, 5-FU (10μg, 100μg, 250μg/ml of DM) or UCMS-IFN-β 
cell CM or a combination of both were added to the MDA 231 cells and cultured for 24 
hours.  The viability of the MDA 231 cells was significantly decreased in a dose-
dependent manner by addition of either 5-FU or UCMS-IFN-β cell CM or combination of 
both in comparison with cells cultured in DM containing 5% FBS.  There was an additive 
effect when MDA 231 cells were cultured both in 5-FU and UCMS-IFN-β cell CM 
compared to when they were cultured in either 5-FU or UCMS-IFN-β cell CM alone 
(data not shown).   
3.4. Effect of UCMS−IFN-β cells and 5-FU on MDA-231 lung tumor burden in 
SCID mice  
Lung tumor burden was significantly reduced in MDA 231 inoculated mice 
transplanted with UCMS−IFN-β cells compared with mice inoculated with MDA 231 cells 
alone (p<0.01)(Figure 5.3).   
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Figure 5.3  Comparative Lung weights. 
Lung weights of mice which were injected with MDA 231 alone compared with mice 
which were injected with both MDA 231 plus UCMS cells or 5-FU or UCMS−IFN-β cells 
or combination of both UCMS−IFN-β cells and 5-FU.  Mice injected with sham tumor 
and sham UCMS cell injections served as untreated controls.  * Statistically significant 
in comparison with mice with MDA 231 only (p-value < 0.01) 
 
Lung weights from mice that received either MDA 231 tumor cells and 
UCMS−IFN-β cells or mice that received MDA 231 tumor cells, 5-FU and UCMS−IFN-β 
cells were not different than control animals (sham tumor and sham UCMS cell injected 
mice).  Histological analysis revealed that engraftment of UCMS cells was detected in 
close proximity or within lung tumor tissues of tumor bearing mice that either received 
SP-DiI labeled UCMS−IFN-β cells or SP-DiI labeled un-engineered UCMS cells (Figure 
5.4 B, D, and E).   
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Figure 5.4 Selective engraftment and therapeutic effect of human UCMS-IFN-β cells in 
combination with 5-FU on MDA 231 lung tumors in SCID mice.   
A: Fluorescent micrograph showing human mitochondrial stained MDA 231 cells (green) 
counterstained with Hoechst 33342 nuclear stain (blue) in mouse lung injected with 
MDA 231 cells alone.  B: Lung section of mouse injected with MDA 231 cells and UCMS 
cells, showing selective engraftment of SP-DiI labeled UCMS cells (red) in close 
proximity to the MDA 231 lung tumors (green).  C: Lung section of mouse injected with 
MDA 231 cells and 5-FU.  D and E: MDA 231 tumor regression and engraftment of 
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UCMS cells in lung sections of mice injected with both MDA 231 cells and UCMS-IFN-β 
cells (D) and in combination with 5-FU (E).  F: Saline control (sham tumor and sham 
UCMS cell injections) lung section negative for UCMS cells after immunostaining with 
anti-human mitochondrial antibody and Hoechst 33342 nuclear stain (blue).  (Scale bar 
=100μm). 
 
No SP-DiI labeled UCMS cells were found in other tissues, such as liver, spleen, 
and kidney.  Tumor area was significantly reduced in all the groups that received either 
UCMS cells, 5-FU, UCMS−IFN-β cells, or both 5-FU and UCMS−IFN-β cells in 
comparison with mice that received only MDA 231 cells (Figure 5.5).  Mice that received 
combined treatment of 5-FU and UCMS−IFN-β cells showed a greater reduction in 
tumor area than the mice that received either 5-FU or UCMS-IFN-β cells (Figure 5.5).  
These results indicate that this combination treatment most effectively reduced the 
tumor burden. 
 
Figure 5.5  Combined effect of 5-FU and UCMS-IFN-β cells on tumor burden.   
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Graph depicting average tumor areas per square 200X field (lung sections) of MDA 231 
tumor bearing mice which were later injected with UCMS cells, UCMS-IFN-β cells, 5-
FU, or combined injections of 5-FU and UCMS-IFN-β cells.  * Statistically significant in 
comparison with mice with MDA 231 only (p-value < 0.05). 
 
4. Discussion 
Here, we provide evidence that 1) in vitro treatment of MDA 231 cells with 
UCMS−IFN-β cell CM significantly increased both early and late apoptosis, and the 
combination of UCMS−IFN-β cell CM and 5-FU showed the greatest reduction in 
aviability of MDA 231 cells; 2) in SCID mice bearing lung tumors due to an inoculation of 
breast adenocarcinoma cells, UCMS cells selectively engraft in tumor tissue; 3) 
systemic administration of UCMS−IFN-β cells or 5-FU to the tumor-bearing SCID mice 
significantly reduced tumor burden; and 4) there was additive tumor attenuation after 
combined low-dose 5-FU and UCMS−IFN-β cells. 
To our knowledge, this is the first report to demonstrate that efficacy of 
combining systemic chemotherapeutic treatment with stem cell-based-targeted delivery 
of a cytokine to a malignant human breast carcinoma in the lungs of SCID mice.  The 
rationale for the combination is that possible toxic side effects are reduced in three 
ways: 1) the targeted delivery of an otherwise toxic cytokine by stem cells circumvents 
many of the effects it would cause if given systemically; 2) it may allow lower doses of a 
chemotherapeutic agent, which is better tolerated by patients; and 3) the two treatments 
may enhance each other.  The dose of 5-FU used here was significantly below the 
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maximal tolerated dose of about 200 mg/kg for mice (Klubes and Cerna, 1983) and the 
5-FU was only administered three times during weekly treatments. 
IFN-β exhibits pleiotropic activities, including immunomodulatory and anti-tumor 
effects (Morris and Zvetkova, 1997;Gresser, 1997).  It stimulates nitric oxide synthesis, 
which in turn inhibits growth and metastasis of some cancer cells (Wang et al., 2001).  It 
activates caspases 3 and 8 (Kito et al., 1999), and induces TRAIL (tumor necrosis-
related-apoptosis-inducing-ligand) synthesis (Morrison et al., 2002).  Interferon-
stimulated genes include XAF 1 (X-linked inhibitor of apoptosis associated factor-1), 
which increases the sensitivity of cells to TRAIL induced apoptosis (Leaman et al., 
2002), and IRF5 (interferon regulatory factor 5), which sensitizes p53-deficient tumors to 
DNA damage-associated apoptosis (Hu et al., 2005).  IFN-β induces p27kip cyclin-
dependent kinase inhibitor and increases phosphorylation of the retinoblastoma gene, 
both of which inhibit proliferation of cancer cells (Kuniyasu et al., 1997).  It inhibits 
angiogenesis by down-regulating basic fibroblast growth factor (Wang et al., 2001).  
Interferon-beta can also inhibit the effect of other growth factors (Einat et al., 1985). 
We have carried out multiple in vitro experiments (cell counting, flow cytometry 
and caspase activation) in order to evaluate the effect of CM from UCMS-IFN-β cells, 5-
FU, or combination of both on MDA 231 cells. Our data clearly indicate that IFN-β 
transfected UCMS cells secreted significant amounts of INF-β (Table1) and induced 
apoptosis of the cancer cells (Figure 1 and 2). Our data also indicated that a 
combination treatment of 5-FU and UCMS-IFN-β CM stimulated activation of caspase 3 
at a low dose of 5-FU (Figure 2).  Although, we did not perform experiments with anti-
IFN-β antibody for the in vitro apoptosis studies, significantly increased IFN-β levels in 
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the CM suggest that IFN-β produced functionally stimulated cancer cell apoptosis.  Our 
results are supported by several other studies in which IFN-β had an apoptotic and 
growth inhibitory effect on MDA 231 cells (Gibson et al., 1993).  CM obtained from 
untransfected UCMS cells also increased early apoptosis index in flow cytometry 
analysis of annexin V (Figure 1). This may suggest that UCMS cell alone may produce 
a factor(s) that stimulate cancer cell apoptosis. However, the mechanism by which 
UCMS cell alone stimulate apoptosis must be addressed by separate study. 
Tumors secrete factors that recruit cells from surrounding tissue as well as from 
the bone marrow to provide support and nutrition (Tlsty and Hein, 2001;van Kempen et 
al., 2003).  Nakamizo et al. showed that SDF1 alpha, EGF and PDGF but not basic FGF 
or VEGF, enhanced bone marrow MSC migration to tumor cells (Nakamizo et al., 2005).  
Breast cancer cells have been reported to make the chemokines CCL5 and CCL2 that 
could cause stem cells to traffic to them (Kulbe et al., 2004).  A therapeutic strategy 
using gene-transfected MSC as cellular vehicles for targeted gene delivery circumvents 
the problem of short life or excessive toxicity of cytotoxic cytokine(s) in vivo.  IFN-β, for 
example, could not have been used effectively as a therapeutic agent because the 
maximum tolerated dose is not high enough to attain these effects when given 
systemically (Studeny et al., 2002).  Studeny et al. demonstrated that injection of IFN-β 
transfected MSCs suppressed tumor growth and prolonged mouse survival without an 
acute increase in blood IFN-β concentration (Studeny et al., 2002). 
The fact that large numbers of UCMS cells can be isolated rapidly is an 
advantage, allowing therapy to be initiated with minimal delay.  This is particularly 
crucial for cancer types for which there is such a short life expectancy that the ‘window’ 
 105
for any given treatment may be quite small (Cohenuram and Saif, 2007).  Therefore, 
UCMS cells engineered to secrete a cytokine such as IFN-β may be a future tool for 
targeted gene therapy of human breast and other cancers via stem cells with or without 
low doses of chemotherapeutic agents such as 5-FU. 
Un-engineered UCMS cells also reduced the tumor burden in tumor-bearing 
SCID mice and in vitro data showed that CM from UCMS cells reduced the MDA 231 
cell viability and proliferation.  These results suggest that UCMS cells alone are capable 
of reducing growth of breast carcinoma cells. Further studies are needed to explain this 
effect. 
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